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1 Introduction	  
1.1 Abstract 
Cancer is the leading cause of death worldwide and CRC is the third most common type. 
Many factors contribute to tumorigenesis including different types of epigenetic alterations of 
cancer-critical genes as seen in tumor suppressor genes and oncogenes. For example genes 
situated in the NDRG family have been demonstrated to contain tumor suppressor effects. The 
NDRG family has been studied in numerous cancer types, but these studies have given 
different conclusions in regard to the function. In this thesis the role of the NDRG family has 
been studied in four different CRC cancer cell lines to investigate whether the promoter 
region of the genes were methylated, and thus epigenetically silenced. Studies have shown 
that MBPs bind to methylated CpG islands and afterwards recruit transferases, which leads to 
the formation of heterochromatin. By isolating RNA from cell lines the thesis showed that the 
MBPs MeCP2, Kaiso, and MBD2 were present at mRNA and protein level. ChIP followed by 
qPCR confirmed the interaction between MBPs and NDRG4 chromatin. Lastly, RNAi was 
performed with esiRNA to see if it was able to knockdown the MBPs and thereby reactivate 
the NDRG genes. No definitive conclusion could be drawn, due to contradictory results. 
However, this study demonstrates that NDRG1 is not methylated, while NDRG4 is methylated 
and interacts with the MBPs MeCP2 and MBD2. 
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1.2 Resume 
Cancer er den sygdom i verden, der er ansvarlig for flest dødfald, og ud af disse er 
coloncancer den tredje mest almindelige type.  
Mange forskellige faktorer bidrager til tumorigenese, heriblandt forskellige typer af 
epigenetiske ændringer af cancerkritiske gener, som det ses for tumorundertrykkende gener 
og onkogener. Som eksempel har man bevist, at NDRG familien indeholder en evne, til at 
undertrykke tumorer. Derfor er denne familie blevet undersøgt i forbindelse med forskellige 
typer kræft, men disse studier har ikke formået at give en entydig konklusion på familiens 
funktion. I dette speciale bliver NDRG familiens rolle studeret i fire forskellige 
coloncancercellelinjer for at undersøge, om genernes promoterregioner er metyleret og derved 
epigenetisk forhindrer dem i at blive udtrykt. Studier har vist, at MBP’er binder sig til 
metylerede CpG øer og derefter rekrutterer transferaser, hvilket leder til formationen af 
heterokromatin. Ved at isolere RNA fra cellelinjer, viste det sig, at MBP’erne MeCP2, Kaiso 
og MBD2 var tilstede både på mRNA- og proteinniveau. ChIP efterfulgt af qPCR bekræftede 
interaktionen mellem MBP’erne og NDRG4 kromatin. Afslutningsvist blev RNAi udført med 
esiRNA for at undersøge, om det var i stand til at undertrykke MBP’erne og derved 
genaktivere NDRG generne. Grundet modstridende resultater, var det dog ikke muligt at nå en 
endelig konklusion. Dog formår dette speciale både at bevise, at NDRG1 ikke er metyleret, og 
at NDRG4 er det og interagerer med MBP’erne MeCP2 og MBD2.    
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1.3 Preface 
Cancer is the leading cause of death worldwide and it has been estimated to account for 8.2 
million deaths alone in 2012 [WHO|Cancer]. In Denmark, 235,000 cases of cancer were 
diagnosed in 2012 and the annual numbers of incidence are expected to increase [Kræftens 
Bekæmpelse; WHO|Cancer].  
Normal cell functions are governed by basic cellular features dictated by the genetic code and 
a network of RNA expression, which both are directed by epigenetic regulations [Tsai & 
Baylin, 2011]. The human genome consists of three billion base pairs with 25,000 genes, of 
which 1.5 % code for proteins. The genes encoding proteins are highly conserved and tightly 
regulated to maintain their function [Esteller, 2011]. The DNA of humans are 99.9 % alike 
and the variations between individuals are caused by single nucleotides polymorphisms, the 
order of genes and by epigenetic alterations etc. [Feuk et al., 2006]. The DNA is tightly 
packed into the nucleus by proteins, where histones are the most common proteins. Histones 
as well as the DNA can be altered, which results in changed gene expression. Cancer arises 
due to alterations in the genes and alterations of their expression, which leads to changes in 
the gene product. 
 
Epigenetics affects the normal cell, as well as the diseased cell, in many ways. The word 
‘epigenetic’ is derived from two Greek words, epi and genno, which translate to ‘in addition 
to’ and ‘give birth to’, respectively [Rodrígues-Paredes & Estelle, 2007; Brait & Sidransky, 
2012]. The term epigenetics refers to changes in the DNA that do not affect the primary DNA 
sequence, but the affected phenotype [Shivapurka & Gazdar, 2010]. Epigenetic variations 
explain phenotypic differences in otherwise genetically identical twins [Brait & Sidransky, 
2012; Esteller, 2008]. 
Epigenetic changes affect which genes are transcribed by signaling to methyl-CpG binding 
proteins (MBPs). MBPs then recruit enzymes that chemically modify the chromatin structure 
by either activating or repressing the gene. Therefore the chemical modification affects which 
proteins the cell produces [Bernstein et al., 2007; Zhang & Pradhan, 2014]. If the epigenetic 
mechanisms become dysregulated, they can lead to many types of diseases including cancer, 
where epigenetic modifications can lead to activation of oncogenes and deactivation of tumor 
suppressor genes (TSGs) [Tsai & Baylin, 2011]. These modifications arise due to changes in 
the functional groups that are connected to the DNA. The different functional groups change 
the affinity between the DNA and its associated proteins leading to silencing of genes, e.g. 
methylation.  
Myelocytmatosis viral oncogene (MYC) is a family of genes coding for transcription factor, 
which first was identified in 1978. In normal tissues MYC levels are not detectable, but in 
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tumors the level of MYC is high. The family consists of several subgroups, of which some 
have neoplastic potential. One of them is neuroblast-derived MYC (N-MYC) [J. Zhang et al., 
2006]. A new group of TSGs is the N-Myc Downstream Regulated Genes (NDRG), which 
have been associated with various human cancers [Lorentzen et al., 2011].  
 
One of the main problems in regard to understanding cancer development is the 
understanding of how gene expression is regulated and how epigenetics affects cellular 
physiology and pathology [Costa, 2010; Issa, 2008]. Today’s technology makes it possible to 
study epigenetic processes and to investigate DNA methylation status of the genes 
[Rodríguez-Paredes & Esteller, 2011]. However, a precise understanding of cancer and the 
effect of epigenetics on a molecular level, as well as the function of the NDRG family, is 
needed to optimize diagnosis, prognosis and to increase the efficiency of individual 
treatments [Costa, 2010]. 
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1.4 Problem field 
For a more thorough understanding of the biology behind cancer it is important to know 
which genes and pathways are involved. The initiation of cancer is due to e.g. activation of 
oncogenes and loss of TSGs.  A relatively new group of TSGs is the NDRG family, which 
consists of four genes, NDRG1-4. The NDRG family has been detected in various tissues and 
it is involved in cellular processes e.g. cell growth and differentiation.  
 
CpG island analyses have shown that NDRG family possesses CpG islands in their promoter 
region and therefore are susceptible to epigenetic regulation at the level of transcription. DNA 
methylation affects gene activity either directly by inhibiting transcription factors, or 
indirectly through MBPs, which recruit histone modifying and chromatin-remodeling 
complexes [Kanwal & Gupta, 2012]. MBPs are recruited to a methylated promoter, which 
attracts histone-modifying enzymes, thus leading to an altered structure of the chromatin. 
Altered chromatin affects gene expression by either expressing or silencing the gene. Various 
studies have been performed in regard of the NDRG family and cancer, which demonstrated 
that the genes are epigenetically altered, often due to methylation. Methylated genes are 
associated with silencing, which is seen for the NDRG genes in various human cancers. 
However, so far no one has examined if and which MBPs are involved in the inactivation of 
the NDRG family. 
 
1.5 Aim 
The aim of the project is to elucidate the function of the MBPs Kaiso, MeCP2 and MBD2 in 
colorectal cancer (CRC). Therefore, quantification of the four NDRGs expression was 
examined in four CRC cell lines followed by establishing if they are epigenetic altered by 
promoter hypermethylation. Subsequently, chromatin-immunoprecipitations (ChIP) analyses 
were used to establish if and which MBPs interact with chromatin and participate in down-
regulation of the NDRG genes. Finally, knockdown through RNA interference (RNAi) was 
performed on each of the interacting MBPs to investigate the possibility of reactivating the 
NDRG genes. 
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2 Theory	  
 
2.1 Cancer 
Cancer exists in many forms and can be developed in all the different compartments of the 
body. The different types of cancer all originate from a single somatic cell that mutates or 
undergoes epigenetic changes. Epigenetic changes are alterations on the DNA that does not 
affect the DNA sequence, which can change a cell into a tumor cell [Ponder, 2001].   
 
Over the years different models have been presented to explain how cancer arises. One of the 
first was the ‘two hit hypothesis’ proposed by Alfred Knudson in 1971. After studying 
retinoblastoma he argued that for a normal cell to become malignant, two hits had to occur to 
suppress both retinoblastoma alleles [Knudson, 1971].  
Today several different ‘hits’ are added to the model before a cell can become malignant. One 
of the hits is epigenetic alteration. Before a lineage of cells can become cancerous, the cells 
must undergo multiple hits of natural selection, genetic mutations, and epigenetic alterations, 
where each hit will increase the likelihood for the next hit to occur [Devilee et al., 2001]. 
According to the hypothesis each hit will promote the cancer’s growth and its ability to avoid 
normal cell regulations [Tsai & Baylin, 2011]. The development of cancer is a 
microevolutionary process that proceeds over multiple steps as illustrated in figure 1, where 
the first hit could initialize the process of turning the cell malignant. The second hit might 
serve to circumvent growth restrictions. The cells with hit 1+2 will eventually replace the 
cells with only one hit. The third hit could inactivate TSGs, or activate oncogenes and these 
new hits will help the 1+2+3 cells to overgrow the cells with only 1+2 illustrated in figure 1  
[Devilee et al., 2001].  
 
Figure 1: The microevolutionary process leading to cancer - The development of cancer happens over a period 
of time where multiple hits occur, which can lead to tumorigenesis. The hits will influence the cancerous pathway 
by making the cancer cells outgrow the normal cells [Modified from Devilee et al., 2001]. 
Throughout decades of investigating how and what makes a cell cancerous, six mechanisms 
have been proposed to be the hallmarks of cancer [Hanahan & Weinberg, 2011]. 
 
1st	  hit 2nd	  hit 3rd	  hit 4th	  hit 
Normal	  cell 
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2.1.1 Hallmarks	  of	  cancer	  
A cancer cell differs from normal cells in several ways, which are called the hallmarks of 
cancer. The six hallmarks of cancer are illustrated in figure 2 [Hanahan & Weinberg, 2011].  
 
Figure 2: Hallmarks of cancer - The six mechanisms that make a cell cancerous [Hanahan & Weinberg, 2011]. 
Not all of the hallmarks are seen in all types of cancer and those who are, are not all are 
necessarily present at the same time.  
For a cell to grow and proliferate, growth factors are released and when they bind they 
enables the cell to enter cell division and proliferate. The release of growth factors is strictly 
controlled in the cell to maintain homeostasis [Hanahan & Weinberg, 2011]. Cancer cells 
develop several ways to both induce and sustain proliferative signals by producing ligands or 
similar growth factors and by avoiding negative feedback loops [Hanahan & Weinberg, 
2011].   
The cancer cells also need to evade growth suppressors, which are often TSGs. Growth 
suppressors prevent cell growth and proliferation and are therefore transcribed when cells 
become abnormal. When the cell becomes abnormal, the retinoblastoma (RB) protein 
transduces stress signals from outside the cell, while the p53 protein receives stress signals 
within the cell. Both RB and p53 are TSGs, which functions in cell cycle arrest, DNA repair 
and apoptosis [Ben-Porath & Weinberg, 2005; Sherr & Mccormick, 2002]. In cancer cells 
TSGs are often found mutated or silenced, which makes it possible for the cell to grow 
despite of its abnormality [Hanahan & Weinberg, 2011].  
 
Angiogenesis is a vital strategy for a tumor to increase its size and to avoid hypoxia during its 
growth. Angiogenesis is a natural process occurring in embryogenesis, wound healing and in 
the female reproductive cycle, all regulated by pro- and anti-angiogenic signals. After a 
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cancer colony reaches 1-2 mm3, it needs to induce angiogenesis due to increased consumption 
of oxygen and nutrients. The cancer cell will undergo apoptosis without adequate oxygen and 
supply of nutrition to the cells, and the colony will be limited in size until new or increased 
blood supply becomes available [Folkman, 2006; Raica et al., 2009].  
When the primary tumor reaches a certain size, many types of cancer will start to become 
invasive and some will enter the bloodstream or lymph system [Chiang & Massagué, 2008]. 
Many of the cancer cells that reach the bloodstream or lymphatic system, will metastasize. 
Metastases are the leading cause of cancer deaths, partly because they can stay dormant until 
the primary tumor is removed and because they are hard to locate [Cancer.dk (n.d.); Bergers 
& Benjamin, 2003].   
Many cancer cells have telomerase, which enable replicative immortality by maintaining their 
telomeres length. All cells have a certain number of times they can divide and proliferate 
before they undergo apoptosis or enter senescence. Both apoptosis and senescence are 
functions dependent on telomeres, which both are regulated by telomerase. The telomeres are 
a repeated sequence of TTAGGGG nucleotides, which protect the chromosome from 
degeneration during its multiple rounds of cell division [Blasco, 2003]. During cell division 
the 3’ end of the chromosome cannot be replicated, due to the lagging strand of the DNA, and 
thus the chromosome will be shorten 50-200 bp during every division [Shay et al., 2001]. The 
telomeres thereby protect the DNA from degradation. Immortal cells, as stem cells, have 
telomerase, which function is to regenerate the telomere and to suppress senescence [Wai, 
2004]. Cancer cells therefore avoid both senesce and apoptosis by having telomerase.  
Cancer cells also have the ability to avoid cell death. Apoptosis is a controlled program that 
leads to a controlled degeneration of the cell. Apoptosis can either be extrinsically or 
intrinsically programmed, which in both cases lead to activation of proteases that are part of 
the caspases cascade. In cancer the proteases can be mutated or altered. The alteration 
involves epigenetic changes and alternative splicing, preventing activation of the caspases, 
thus apoptosis can be avoided [Favaloro et al., 2012]. Many of the hallmarks are gained due 
to alterations in oncogenes and TSGs. 
 
2.1.2 Oncogene	  and	  tumor	  suppressor	  genes	  
In normal cells, genes that stimulate cell proliferation and differentiation are referred to as 
proto-oncogenes, whose function is to help regulate cellular growth as seen with mitogens 
and growth. When proto-oncogenes are altered as seen in cancer, the genes become 
hyperactive and are called oncogenes [Liu et al., 2009]. Oncogenes are genes with the 
potential to promote cancer in normal cells and they are often found mutated in tumor cells. 
Some alterations directly affect the DNA sequence, while other alterations affect the 
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regulation of a gene, as seen with epigenetic changes. All of these alterations either make the 
gene hyperactive or cause the gene to overproduce the encoded protein, as illustrated in figure 
3. 
 
Figure 3: Alteration of proto-oncogene – A proto-oncogene can become an oncogene due to mutations, 
chromosome rearrangement or by epigenetic alterations [Modified from Alberts et al., 2008]. 
 
A hyperactive gene is either permanently active or activated in ways, in which the wild type 
gene would not be activated, leading to imbalance in the cells, as seen for MYC where the 
gene is amplified [Croce, 2008]. When an oncogene becomes active it often leads to gain-of-
functions, which means that the protein gets new activity, compared to the wild type 
[Vogelstein & Kinzler, 2004]. Oncogenes are dominant, which means that only one allele has 
to be altered in the proto-oncogene, for the oncogene to become active [Lodish et al., 2000]. 
The product of an oncogene can affect various cellular functions by affection e.g. 
transcription factors, growth factors and apoptosis regulators [Croce, 2008]. 
 
TSGs function opposite of oncogenes, as it prevents abnormal cellular activity and thus 
suppresses genes that are cancerous. Inactivation of a TGS leads to loss-of-function, where 
both alleles have to be altered [Lodish et al., 2000]. The loss of a TSG will increase the 
likelihood of tumorigenesis [Luo et al., 2009]. Both genetic and epigenetic mechanisms can 
inactivate TSGs, as is the case for proto-oncogenes.  
Alterations in both oncogenes and TSGs are found in all cancer types, e.g. colorectal cancer 
(CRC). 
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2.1.3 Colorectal	  cancer	  
CRC arises from the colon or the rectum. These forms of cancer have been categorized under 
the same name because of their similarities in development, prognosis, and treatment 
[Bardhan & Liu, 2013; Shivapurka & Gazdar, 2010].   
CRC is the third most common type of cancer globally with 1-2 million new cases each year 
[Brenner et al., 2014]. The development of CRC is a slow process, and the median age of 
diagnosis is 70 year [Brenner et al., 2014]. It is estimated that the entire process, from the first 
cellular alterations until cancer is developed, takes approximately 10 years [Bradhan & Liu, 
2013]. CRC is a multistep process, where accumulations of genetic and epigenetic changes 
are seen in the mucosa cells, affecting oncogenes, TSGs, and non-coding RNA [Migheli & 
Migliore, 2012; van Engeland et al., 2011].  
 
CRC incidence rates are highest in the western world for men over 50. The risk of getting 
CRC is associated with a family history of CRC, inflammatory bowel disease, smoking, 
obesity, etc. [Cunningham et al., 2010]. However, CRC do not have a specific risk factor that 
accounts for the majority of cases [Bardhan & Liu, 2013]. The symptoms of CRC are non-
specific, but they often involve abdominal pain, bleeding, weight loss, fatigue and change of 
bowel habits [Labianca et al., 2010]. CRC is often found by screening programs, which have 
raised the 5-year survival to 65 % [Brenner et al., 2014]. Only 3-5 % of the CRC cases are 
inherited, where important TSGs or DNA repair genes are inactivated. This requires 
alterations in both of the alleles of the gene before an inactivation can occur. Often one of the 
alleles are monoallelic altered in the germ line and a second hit (somatic alteration) occur 
later in life, leading to tumor transformation in the cell [Brenner et al., 2014]. 
 
The diagnosis of CRC is determined from the results obtained by endoscopy [Cunningham et 
al., 2010]. Once the diagnosis is given, the stage of the cancer is categorized by the tumor-
node-metastasis (TNM) classification system [Labianca et al., 2010].  
CRC is divided into subgroups, one of them focusing on the effect of epigenetic 
modifications. This subgroup is called CpG island methylator phenotype (CIMP) where a 
high level of CpGs is methylated (CpG is further explained on page 7). CIMP is found in 
approximately 25 % of the sporadic CRC, of which 30-40 % are found in the proximal colon 
and 3-12 % of the distal colon and rectal tumors [Migheli & Migliore, 2012; Lao & Grady, 
2011; Bardhan & Liu, 2013]. From an epigenetic point the CIMP group can additionally be 
divided into three groups, CIMP1-3, according to the levels of methylated CpG island (CGI) 
and which gene is mutated [Shen et al., 2007]. CIMP1 has a high level of methylated genes, 
while the second group CIMP2 has a limited amount of methylated genes, and the last group 
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rarely has methylations at all, but instead has a p53 mutation [Coppedè, 2014; Migheli & 
Migliore, 2012].  
Several methylated genes have been identified in CRC, as is the case for p53, which is found 
mutated in 50 % of CRC cases [Grady & Pritchard, 2014]. However, some of the methylated 
genes are only expressed in the transition from normal tissue to aberrant crypt focus. Others 
are only found in the late stage of CRC and are associated with metastasis [Coppedè, 2014; 
Lao & Grady, 2011]. The epigenetic changes can be used as biomarkers, as the DNA 
methylation is stable marks for CRC and because DNA methylations are easy to detect [Taby 
& Issa, 2010].  
CRC is a heterogenetic disease, which is why the distinction between subgroups is important 
in regards to prognosis as well as treatment [Coppedè, 2014; Bardhan & Liu, 2013]. The 
methylation status could potentially give a more accurate picture of the prognosis, as well as 
help to choose the correct type of treatment. Both CIMP1 and CIMP2 are associated with 
cancer in the proximal part of the colon, but CIMP1 associated with a better prognosis than 
CIMP2 [Migheli & Migliore, 2012]. CRC is primarily treated by surgery, but the success rate 
decreases the more advanced the tumor is. Therefore many studies have been performed to 
clarify how CIMP and drug treatment correlates [X. Li et al., 2014]. Ogino and colleagues 
(2007) demonstrated that using fluorouracil as treatment for CIMP CRC was ineffective 
[Ogino et al., 2007]. Rijnsoever and colleagues (2003) however demonstrated that CIMP1 
patients benefitted from fluorouracil treatment [Rijnsoever et al., 2003]. Thus, it is difficult to 
conclude anything definitive on the predictive role of epigenetic alteration in regard to 
treatment. However, epigenetic regulation is affected by many factors and some of these 
causes the epigenetic mechanisms to become dysregulated. Some of these factors will 
therefore be discussed in the following sections to give the necessary foundation of 
knowledge, needed to understand this thesis. 
 
2.2 Epigenetics 
Epigenetics is the study of DNA and histone modifications and was first introduced in 1942 
by Conrad Waddington, who studied developmental changes in Drosophila melanogaster 
[Brait & Sidransky, 2012; Zhang & Pradhan, 2014]. Epigenetics is a natural process 
important in various biological mechanisms e.g. development and cell cycle control, thus it 
affects all humans throughout their whole existence. Epigenetic alterations change the 
genome by different mechanisms such as DNA methylation, chromatin and histone 
modification, and by non-coding RNA [Zhang & Pradhan, 2014].  
DNA methylation occurs on the cytosine base, while the histone modification occurs on the 
histone tails of the chromatin, which affects the post-transcriptional structure of the histone. 
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This is due to an addition of a functional group to the DNA, which alters the histone 
interaction with the DNA and recruit proteins [Brait & Sidransky, 2012; Kim et al., 2009]. 
Non-coding RNA on the other hand affects mRNA by either degrading it or by inhibiting its 
translation [Esteller, 2011]. Some of the modifications are long-term, as is the case for DNA 
modifications whereas others are reversible as seen for histone modifications [Cedar & 
Bergman, 2009; Berdasco & Esteller, 2010].  
 
2.2.1 DNA	  methylation	  
DNA methylation refers to a covalent binding of a methyl group (CH3) to the DNA. In the 
mammalian genome, DNA methylation affects the cytosine ring at the 5’ position as 
illustrated at figure 4 [Taby & Issa, 2010; Kim et al., 2009].   
 
Figure 4: Epigenetic methylation – Conversion of cytosine to 5-Methylcytosine, by addition of a methyl group 
(CH3) to the 5´posistion. The methyl groups are donated from S-adenosyl methionine (SAM) [Gibney & Nolan, 
2010] 
The methyl group is donated from S-adenosyl methionine (SAM) and when it is bound to the 
cytosine ring, which then is denoted 5-methylcytosine [Taby & Issa, 2010; Gibney & Nolan 
2010]. The modified cytosine is primarily found 5’ to guanine, which together are called CpG 
sites, indicating that the cytosine and the guanine are linked together by a phosphate in the 
DNA [Brait & Sidrasky, 2012].  
 
DNA methylation can lead to low or no transcriptional activity because of its condensing 
effect on the DNA. By making the DNA more compact it makes the DNA less available for 
the transcriptional machinery. DNA methylation is primarily found on CpG islands, which 
makes them an important epigenetic feature.  
 
2.2.1.1 CpG	  islands	  
As mentioned, CpG sites are CG dinucleotides. The genome consist of approximately 3 
billion base pair (bp), whereof approximately 28 million is CpG sites, which means that the 
CpG sites account for less than 1 % of the genome [Portela & Esteller, 2010; Stirzaker et al., 
2014]. CpG sites can be found throughout the entire genome, however most of the CpGs are 
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found in islands (CGI) [Stirzaker et al., 2014]. The CGI consists of at least 200 bp where the 
ratio of GC is observed to be greater than 60 % [Kim et al., 2009]. Further, the CGI is found 
in the 5’ promoter region in 60 % of all human genes and these regions are associated with 
gene regulation [Illingworth & Bird, 2009; Moore et al., 2013].  
The CGI regions are most often found in promoter regions, whereas the poor regions are 
associated with repetitive sequences, transposons and non-coding regions. The poor regions 
are methylated in normal cells, and thus not transcribed [Bernstein et al., 2007; Rodríguez-
Paredes & Esteller, 2011]. The CpGs in the CpG-poor regions are often found methylated, 
while the CGIs are often found unmethylated in normal cells [Costello et al., 2000; Moore et 
al., 2013]. This is illustrated in figure 5, where the black circles indicate methylation and 
white circles indicate unmethylated CpGs. 
 
Figure 5: Methylation status on CpG island in normal cell – Methylated CpGs are illustrated as black circles 
and unmethylated CpGs are illustrated as white circles. CpGs are unevenly distributed in the genome, but they are 
often clustered in CpG islands in the promoter regions. When CpG islands are unmethylated they are associated 
with an active gene [Stirzaker et al., 2014] . 
CGI promoters are often associated with housekeeping genes, which are involved in DNA 
repair and cell cycle genes. For a cell to function, these genes must be transcribed and 
therefore their promoter must be unmethylated [Zhang & Pradhan, 2014]. Around 6 % of the 
CGI are methylated in the normal cell, which is necessary to have differentiated tissue. CGIs 
are therefore identified as tissue-specific [Portela & Esteller, 2010]. A study of bioinformatics 
conducted by Straussman and colleagues (2009) indicates that the tissue-specific methylation 
percentage may be higher than previously assumed [Straussman et al., 2009].  
However, before the CGIs can become methylated DNA methyl transferases are necessary.  
 
2.2.1.2 DNA	  methyl	  transferases	  	  
Epigenetic mechanisms are dynamic and thus the changes are reversible. DNA methylation is 
catalyzed by DNA methyltransferases (DNMT), which in mammals are divided into three 
types: DNMT1, DNMT3A and DNMT3B.  
The DNMT1 is called the ‘maintenance methyltransferase’ because of its role in maintaining 
the DNA methylation status under cell division and differentiation [Jones & Liang, 2009; 
Taby & Issa, 2010]. This enzyme prefers hemimethylated DNA from where it can methylate 
CpG in the newly synthesized strand [Bernstein et al., 2007]. DNMT3A and DNMT3B are 
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referred to as ‘de novo’ methyltransferases and are used in the cell to methylate unmethylated 
DNA e.g. during replication as illustrated in figure 6 [Kim et al., 2009; Jair et al., 2006].   
 
Figure 6: The function of the DNA methyltransferase family – There are three types of DNA 
methyltransferases (DNMT), called DNMT1, DNMT3A and DNMTB. DNMT1 is known as the maintenance 
transferase. DNMT3A and DNMTB are called the ‘de novo’ transferases, due to their function in methylation of 
unmethylated DNA [Jones & Liang, 2009]. 
After the functional methyl groups have been added by the DNMTs additional proteins are 
required for the dynamic processes to be performed. This is done by recruiting methyl-CpG 
binding proteins.   
2.2.1.3 Methyl	  CpG-­‐binding	  protein	  family	  
DNA methylation functions as a signal, which recruits members of the MBP family [Parry & 
Clarke, 2011; Tsai & Baylin, 2011]. The role of the proteins was established in the 1980s 
where they were discovered to bind to methylated CpGs [Parry & Clarke, 2011].  
This family of proteins has multiple roles in gene regulation and many studies have shown 
their effect in tumorigenesis, due to their ability to interpret the DNA methylation signal and 
recruit enzymes that affect both the histones and the DNA [Tsai & Baylin, 2011]. 
 
The MBP family is a large group of proteins and is subdivided into three branches according 
to their different domains: Methyl CpG-binding domain (MBD) containing proteins, methyl-
CpG binding zinc fingers and the SET and RING finger-associated (SRA) domain containing 
proteins [Parry & Clarke, 2011]. All the MBPs have been associated with transcriptional 
repression because of their ability to recruit co-repressor, which can initiate heterochromatin 
formation. These groups have various subgroups, but in this thesis only MeCP2, MBD2 and 
Kaiso will be described. 
 
2.2.1.3.1 The	  methyl	  CpG-­‐binding	  domain	  containing	  family	  	  
The MBD containing family is the largest of the three and is subdivided into three 
additionally groups: HMT-MBD, MeCP2-MBD, and HAT-MBD. 
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In the MeCP2-MBD group both MeCP2 and MBD2 are found, thus only this group will be in 
focus here.  
 
MeCP2 and MBD2 both have a MBD domain and a transcript repression domain (TRD). The 
MBD domain function by binding to methylated DNA, while the TRD domain regulates 
transcription [Liyanage et al., 2014; Zhigalova et al., 2010]. Both proteins can lead to 
transcriptional gene silencing through their TRD domains [Bogdanović & Veenstra, 2009]. 
MBD2 structually differs from MeCP2 as illustrated in figure 7. MBD2 has a 140 amino acid 
region containing repetitions of glycine and arginine residues (GR repeat), but the function of 
the region is currently unknown [Berger & Bird, 2005].  
 
 
MeCP2 
MeCP2 is a nuclear protein that is found in several tissues, especially in the brain, and it is 
associated with silencing of genes [Klose et al., 2005; Ezeonwuka & Rastegar, 2014]. 
MeCP2’s biological function is unclear, but studies have shown that it recruits the DNA 
transferase histone deacetylation (HDAC) enzymes, which remove acetyl when it is bound to 
methylated CpG, thus functioning as a chromatin architectural protein [Woodcock, 2006; 
Liyanage & Rastegar, 2014].  
To elucidate the function of MeCP2, various mouse models have been established of which 
knockdown, mutation and knock-in models are the most common. Both mutation and deletion 
of MeCP2 in mice are associated with neurodevelopmental disorders e.g. Rett syndrome 
[Vucic et al., 2008; Z. Zhou et al., 2006]. A study performed by Guy and colleagues (2001) 
elucidated the function of MeCP2 by using MeCP2 knockout mice. MeCP2 was knocked-out 
by replacing exon 3 and 4, which abolished the protein [Liyanage & Rastegar, 2014; Guy et 
al., 2001]. The abolished protein was transferred to a target vector that was injected into a 
blastocyte, which was then transferred into a pseudo-pregnant mouse. The null-mice pups 
were viable and fertile, but after six weeks spontaneous movements, affected posture and 
altered breath were observed. This corresponded to neurological symptoms as seen in the Rett 
syndrome [Guy et al., 2001]. Further, a study performed by Schaevitz and colleagues (2013) 
used knock-in mice to introduce a nonsense point mutation in MeCP2 to examine the mice 
Figure 7: The structure of Methyl-CpG-binding domain (MBD) containing family MeCP2 and MBD2 – 
MeCP2 and MBD2 both share the MBD and the transcription repression domain (TRD). The function of the two 
domains is to bind the methylated DNA and regulate transcription respectively. MBD2 also has glycine and 
arginine repeats (GR repeats) [modified from Liyanage et al., 2014]. 
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behavior. In the study the MeCP2R168X mutation resulted in underweighted mice with impaired 
motor coordination, compared to the wild type, symptoms that are also seen in Rett syndrome 
[Schaevitz et al., 2013]. Thus MeCP2 affects neurodevelopment. 
 
MBD2 
MBD2 is a nuclear protein primarily found in the nucleus of the cell. MBD2 exists in three 
isoforms, MBD2a, MBD2b and MBD2c, which arises due to alternative splicing. The full 
length MBD2 protein is the MBD2a. The MBD2b has a truncated N-terminus, lacking the GR 
repeat, and the MBD2c isoform lacks the C-terminus. The MBD2c are most commonly found 
in the testes [Berger & Bird, 2005; Menafra & Stunnenberg, 2014].  
MBD2 can bind to methylated DNA when either CpGG or CpGC sequences are present, 
where after it directs methyltransferases and chromatin remodeler to the methylated promoter, 
which leads to gene silencing [Liyanage et al., 2014; Parry & Clarke, 2011]. MBD2 is the 
methyl-binding component in a complex referred to as the MeCP1 complex, which consists of 
multiple transferases enzymes e.g. HDAC [Sansom et al., 2007]. MBD2 associates with many 
types of transferases, which in most cases lead to repression [Bogdanović & Veenstra, 2009]. 
Hendrich and colleagues (2001) elucidated the function of MBD2 in mice. In their study, 
MBD2 was mutated to create null-mice by intercrossing heterozygous mice, which gave 
homozygous Mbd2(-/-) pups according to the expected 1:2:1 ratio. The null-mice where 
healthy, normal looking and fertile, but the progeny of two null-mice was smaller compared 
to the wild type pups. However, the weight difference was equalized after weaning. The 
difference was due to a maternal behavior, where the pups were not fed enough [Hendrich et 
al., 2001]. Hendrich and colleagues hypothesize that, due to MBD2 function in transcriptional 
repression, expression of other genes might be altered. 
 
2.2.1.3.2 The	  methyl-­‐CpG	  binding	  zinc	  finger	  domain	  	  
The methyl-CpG binding zinc finger domain group consists of three proteins, which all have 
a 3-finger motif in common. Here only Kaiso will be in focus. 
 
Kaiso 
Kaiso lacks the MBD, which is seen in the other MBPs. However, Kaiso has two functional 
domains: The broad complex, tramtrack, bric a brac/pox virus zinc finger (BTB/POZ) domain 
and the zinc finger domain as illustrated in figure 8 [Sansom et al., 2007]. These domains are 
important for respectively protein-protein interaction and DNA-binding [Zhigalova et al., 
2010]. Kaiso is a nuclear protein, but is also found in the cytoplasm, where it acts as a 
transcriptional repressor protein, which can bind both methylated DNA and unmethylated 
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DNA [Soubry et al., 2005; Kelly et al., 2004; Zhigalova et al., 2010]. Here, the methylated 
form is a double CpG site (CGCG) whereas the unmethylated form is referred to as the Kaiso 
binding site (TCCTGCNA) [Filion et al., 2006]. Kaiso binds to CpG through its triple zing-
finger motif, where it requires at least two methylated CpG dinucleotides [Sansom et al., 
2007]. A study performed by Daniel and colleagues (2002) demonstrated through a deletion 
study that only zinc finger 2 and 3 were necessary to mediate DNA-binding [Daniel et al., 
2002]. 
 
 
Figure 8: Structure of the methyl-CpG binding zinc finger domain protein Kaiso – Kaiso is a part of the 
ethyl-CpG binding proteins (MBPs), but differs from the other by lacking the MBD. Instead Kaiso has a BTB/POZ 
domain and three zinc finger domains (Zn2+). These domains are important for protein-protein interaction and 
DNA binding respectively [modified from Liyanage et al., 2014]. 
Kaiso was initially discovered as a p120 catenin interaction protein, but throughout the years 
it has been demonstrated to interact with many other proteins e.g. nuclear receptor co-receptor 
(N-CoR) [Bogdanović & Veenstra, 2009].  
Kaiso functions as a transcriptional repressor in the nucleus where it directs N-CoR to the 
promoter region. The N-CoR is a complex that contains transferases, which promotes 
methylation and deacetylation of the DNA, thus leading to heterochromatin formation [Parry 
& Clarke, 2011; Yoon et al., 2003]. It has been hypothesized that Kaiso can lead to gene 
silencing by methylation through a signal transduction pathway with p120 catenin and N-CoR 
and thereby transmit signals from the cell surface to the nucleus [Prokhortchouk et al., 2001].  
 
Lopes and colleagues (2008) demonstrated Kaiso’s contribution to epigenetic silencing in 
HCT116 and Colo320 cell lines, by showing that Kaiso altered the promoter of TSGs 
CDKN2A, HIC1 and MGMT by repression [Lopes et al., 2008]. These genes are involved 
respectively in cell cycle arrest (through the cyclin D–cdk4/6 complexes), p53 damage 
response and DNA mismatch repair. Other studies have demonstrated that Kaiso affect cell 
cycle through cyclin D1 [Donaldson et al., 2012]. After Lopes and colleagues (2008) 
demonstrated that Kaiso binds the methylated promoter of genes, siRNA was used to 
knockdown the Kaiso protein and compared to untreated cells. This demonstrated reactivation 
of the genes, without changing the levels of DNA methylations, thus indicating that 
methylation of genes alone is not enough to silence genes [Lopes et al., 2008].  
Other factors can affect the DNA indirectly by altering chromatin, which also involves the 
histones, the main proteins that pack the DNA.  
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2.2.2 Chromatin	  and	  histones	  
In the cell, DNA is packed into very compact structures called chromatin to fit into the nuclei. 
Chromatin consists of DNA and protein and can exist in two forms; either as heterochromatin 
or euchromatin, which is the silent and active form, respectively. The chromatin can shift 
between the two forms as a result of either modifications on the DNA or the proteins called 
histones [Kim et al., 2009].  
Histone modification can be divided into two different groups according to their effect: 
Global chromatin environment formation and DNA-based biological function. Histone 
modification makes a global environment by altering the chromatin into domains of 
euchromatin or heterochromatin, where the DNA-based modification affects the chromatin to 
perform a task. This could be an activation of a DNA repair gene, where the chromatin has to 
be unraveled, manipulated, and then put back to its original form [Kouzarides, 2007; Ma et 
al., 2005].  
 
2.2.2.1 Histone	  structure	  
Chromatin is DNA that is wrapped around a histone octamer, which is formed out of four 
molecules: H2A, H2B, H3, and H4. The octamer consist of two of each of these molecules 
[Mohtat & Susztak, 2010; Marmorstein & Trievel, 2009].  
To form the octamer, H2A and H2B form a dimer and connect with another H2A-H2B dimer, 
which results in a tetramer. The H2A-H2B tetramer connects to H3-H4 tetramer to form an 
octamer, as illustrated in figure 9A. The chromatin is condensed by the linker histone protein 
H1, which angles the histone core correctly to the DNA so they form a solenoid form as 
shown in figure 9B [Bhaumik et al., 2007; Woodcock, 2006]. The chromatin and its proteins 
are commonly referred to as the nucleosome and are composed of 147 base pair of DNA, that 
are wrapped 1.65 times around the octamer, resulting in 14 contact points between them [Li et 
al., 2007]. The octamer is crucial for the DNA to be packed optimally into the nucleus as seen 
in figure 9C. 
 
Histones and DNA are attracted to each other because of their different charges: Histones are 
positively charged because of lysine and arginine residues, while DNA is negatively charged 
because of its phosphate groups in the backbone. This creates a high affinity beween DNA 
and histones. Histone modifications can influence the affinity by either neutralizing, 
removing or adding functional groups to the residues [Kim et al., 2009]. 
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Figure 9: Histone structure and function – A: The formation of the histone octamer. The histone consists of four 
proteins: H2A, H2B, H3 and H4. H2A and H2B form a tetramer, which connects with a H3 and H4 tetramer. B: 
H1 is a linker histone, whose function is to angle the octamer correctly to the DNA, so the DNA can be packed 
optimally. C: The different stages of the DNA packing until the chromosome formation [Alberts et al., 2008]. 
The octamer subunits have a globular C-terminal domain and an unstructured N-terminal tail. 
The N-terminal tail is associated with post-transcriptional modifications, where the functional 
group is either added or removed to the N-terminal [Kim et al., 2009]. The chromatin consists 
of many N-terminals where the different N-terminals can be affected by different 
modifications [Bernstein et al., 2007]. The post-transcriptional modifications are important 
for transcription, replication, DNA repair and cell cycle regulation [Bhaumik et al., 2007]. 
 
2.2.2.2 Modification	  of	  histones	  and	  chromatin	  
Histone modification occurs on residues, when different functional groups such as methyl, 
acetyl, phosphate and ubiquitin among others, are added or removed [Esteller, 2008; Cedar & 
Bergman, 2009]. However, only methylation will be the focus in this thesis. 
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Chromatin-modifying enzymes, also known as transferases, catalyze the different post-
transcriptional modifications of the histone. In the human body, various types of transferases 
exist and most these are specific for each of the functional groups as illustrated in figure 10. 
The two transferases for methyl are histone methyl transferase (HMT), which transfers a 
methyl group to the histone, and histone demethylase (HDMT), which removes a methyl 
group. By altering the number of functional groups on the histones, and thus the chromatin, 
the transferases affect the affinity between histones and DNA due to the change in the 
nucleosomes’ net charge. This either loosens or tightens the DNA-histone interaction [Li et 
al., 2007].  
 
Figure 10: Histone modification and the transferases responsible – Histone modification involves 
rearrangement of functional groups. The modifications occur on the histone tail, where the functional groups have 
specific residues they can affect. The post-modification occurs due to the transferase, which is specific for each of 
the functional groups. Methyl groups are transferred to the histone tail by histone methyl transferase (HMT) and 
removed by histone demethylase (HDMT) [Füllgrabe et al., 2010]. 
 
The modifications have been proved to affect over 60 different residues in the DNA, but due 
to the complexity of the modifications it is very likely to affect even more residues 
[Kouzarides, 2007]. In mammals, histones are methylated on lysine, arginine, or in some 
cases both. Both arginine and lysine can be methylated on histone H3 or H4, but only at 
specific positions [Bhaumik et al., 2007]. For lysine this can be either in mono-, di-, or 
trimethylated forms, while arginine only can be in mono- or dimethylated forms. For each of 
these forms a different transferase is required [Kouzarides, 2007; Y. Zhang & Reinberg, 
2001]. The number of residues that can be modified combined with the different forms of 
modification give numerous possibilities to the amount of functional responses the cell can 
make due to epigenetic changes [Kouzarides, 2007]. This is referred to as the histone code, 
where the system of epigenetic marking leads to specific regulation and cellular function [Chi 
et al., 2010]. 
While DNA methylation and modifications of the chromatin and histones plays a significant 
role in epigenetic alterations, non-coding RNAs (ncRNA) should also be mentioned. 
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2.2.3 Non-­‐coding	  RNAs	  
Over the past few decades it has been shown that even more of the non-protein-coding part of 
the genome influences cellular processes. Among these are the ncRNA, which are divided 
into several subgroups that have been categorized according to their function and length 
[Esteller, 2011]. The most widely studied subgroups are the microRNA (miRNA) family and 
the small interfering RNA (siRNA) [Esteller, 2011]. 
Both miRNA and siRNA consist of 21-25 nucleotides. They function as gene regulators, 
working by either inhibiting mRNA translation or by degrading the mRNA post-
transcriptionally as seen in figure 11 [Li et al., 2010; Vucic et al., 2008]. miRNA is encoded 
in the genome and transcribed to a primary-miRNA (pri-miRNA). The pri-miRNA is cleaved 
by the RNase III enzyme Drosha, which leads to a 70 nucleotide precursor-miRNA (pre-
miRNA) that is transported out of the nucleus to the cytoplasm by the transporter Exportin 5 
[He & Hannon, 2004]. Once the pre-miRNA reaches the cytoplasm, a second RNase III 
enzyme called Dicer, cleaves the pre-miRNA, this results in the formation of a dsRNA duplex 
containing the mature miRNA and its complementary strand. When the duplex unwinds, the 
mature miRNA will assemble into a RNA-induced silencing complex (RISC).  
In the RISC, the miRNA and siRNA work by binding to the 3’ untranslated region (3’UTR) 
of the target mRNA. This activates the argonaute protein that cleaves or inhibits the mRNA 
[Sharma et al., 2010; He & Hannon, 2004]. Likewise, siRNA in the cytoplasm exists as a 
double stranded RNA that gets cleaved by Dicer, which generates a duplex that ultimately 
assembles into the RISC [He & Hannon, 2004]. 
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Figure 11: Post-transcriptional silencing of mRNA by miRNA and siRNAs – miRNA and siRNA are affecting 
mRNA to be transcriptionally repressed or cleaved. miRNA is transcribed to primary-miRNA in the nucleus  and 
cleaved by Drosha into a pre-miRNA. The pre-miRNA is transported into the cytoplasm by exportin 5, where 
Dicer cleaves it to the mature miRNA. Dicer likewise cleaves the siRNA in the cytoplasm. The mature miRNA 
and siRNA assembles into a RNA-induced silencing complex (RISC). The RISC binds to the 3’ untranslated 
region of the target mRNA, which cleaves the mRNA or inhibits the mRNA translation [He & Hannon, 2004]. 
It is estimated that miRNA regulates approximately 60 % of the protein coding genes. 
miRNA and siRNA are vital for normal cellular function and are involved in many cellular 
processes as proliferation, differentiation, and apoptosis [Kanwal & Gupta, 2012; Esteller, 
2011].  
miRNA can functions as both TSGs and oncogenes and it has been demonstrated that they are 
regulated by DNA methylation [Berdasco & Esteller, 2010; Bardhan & Liu, 2013]. miRNA is 
therefore epigenetic regulated and alteration of miRNA expression can led to a cancerous 
pathway [Migheli & Migliore, 2012]. 
 
2.2.4 Epigenetics	  and	  cancer	  
In 1983 Feinberg and Vogelstein demonstrated that CRC is connected with epigenetic 
alterations, e.g. global DNA hypomethylation and hypermethylation of CpG promoter regions 
[Feinberg & Vogelstein, 1983 A; Feinberg & Vogelstein, 1983 B].  
  Page 18 of 94 
The molecular mechanisms leading to cancer have been studied for decades and for the past 
40 years, epigenetic aberrations associated with cancer have been thoroughly studied [Mohtat 
& Susztak, 2010; Parry & Clarke, 2011].  
 
As previously mentioned, cancer can be a result of DNA methylation and/or DNA 
demethylation, as well as chromatin alteration and histone modification. All of these 
epigenetic mechanisms affect tumorigenesis because of their ability to inactivate TSGs and to 
activate oncogenes [Taby & Issa, 2010]. In cancer cells, TSGs are often found inactivated due 
to epigenetic silencing, which is categorized as CIMP in e.g. CRC [Grady & Pritchard, 2014]. 
In general, silencing is associated with methylation of the gene while activation of oncogenes 
is associated with demethylation. Both of these can lead to cancer as illustrated in figure 12. 
In terms of DNA methylation, cancer cells show genome-wide hypomethylation and site-
specific CpG island promoter hypermethylation [Stirzaker et al., 2014].  
 
 
Figure 12: Epigenetic alteration of tumor suppressor genes and oncogenes - The left side illustrates the 
inactivation of a tumor suppressor gene (TSG) that is transcribed in healthy cells. Inactivation of TSGs will lead to 
tumorigenesis. The alteration can be a result of methylation of the CpG islands. The right side illustrates epigenetic 
alteration of an oncogene, which is normally not transcribed in healthy cells. This alteration can be caused by 
demethylation of the chromatin. Modified from [Sharma et al., 2010] 
DNA hypermethylation has been shown to play a major role in tumor initiation and 
progression [Issa, 2008]. Studies have also shown that epigenetic mechanisms such as 
hypermethylations provide a basic ground for accumulations of genetic and epigenetic errors 
[Taby & Issa, 2010; Issa, 2008].  
More than 300 genes and gene products have been associated with epigenetic alterations in 
regard to human cancer [Kanwal & Gupta, 2012]. Therefore, due to the many ways of which 
TSGs effect can be altered, sporadic cancer is more often caused by epigenetic changes than 
genetic changes [Issa, 2008]. This is also seen forr CRC [Taby & Issa, 2010].  
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Epigenetic silencing can be found in all stages of cancer development and in all the hallmarks 
of cancer where both DNA repair genes, regulatory genes and apoptotic genes are affected. 
This is seen for the DNA repair gene hMLH1 which is highly associated with the 
development of CRC and often methylation in CRC [Nakagawa et al., 2001]. Studies have 
shown that epigenetic silencing of CDKN21 alters the control of cell regulation and that 
silencing of CDH1 affects migration and invasion [Tsai & Baylin, 2011]. ]. Apaf-1 is found to 
be inactivated due to epigenetic alterations, which leads to inaccurate apoptosome formation. 
As mentioned, caspases are also found to be altered in several ways, which affects both the 
intrinsic and extrinsic pathways [Favaloro et al., 2012]. Further, methylation of lysine 27 in 
histone 3 is implicated in apoptosis [Füllgrabe et al., 2010].   
 
As mentioned, MBPs interpret methylations of the DNA and therefore misregulation can lead 
to tumorigenesis [Sansom et al., 2007]. Numerous studies have been performed to elucidate 
the role of MBPs. 
MBD2 has been demonstrated to be up-regulated in some cancer types and down-regulated in 
others, thus the results are contradictory. Campbell and colleagues (2004) demonstrated the 
effects of MBD2 in cancer by using antisense oligonucleotides to knockdown MBD2 both in 
vivo and in vitro. Both the in vivo and the in vitro study showed that MBD2 affects 
tumorigenesis positively [Campbell et al., 2004]. Not many studies have been performed 
linking MeCP2 to cancer [Sansom et al., 2007]. Pancione and colleagues (2010) 
demonstrated that MeCP2 was a part of transcriptional silencing in cancer. This was 
illustrated by 5’-aza-2’-deoxycytidine treatment of CRC cell line, e.g. HCT116, which led to 
reactivation of silenced TSGs [Pancione et al., 2010]. 
To determine the role of Kaiso, null-mice were generated. The Kaiso-/- mice were healthy, 
fertile and showing no alteration compared to the wild type [Prokhortchouk et al., 2006]. 
Prokhortchouk and colleagues (2006) further investigated the effect of Kaiso in cancer, by 
crossing Kaiso deficient mice with ApcMin/+ mice, which are susceptible for tumor 
development. They found that the Kaiso null-mice had a later onset of tumorgenesis in 
intestinal cancer and that the Kaiso protein was increased in multiple CRC tumors 
[Prokhortchouk et al., 2006]. This led to the conclusion that Kaiso has a positively effect in 
tumorigenesis. Lopes and colleagues (2008) demonstrated that Kaiso led to tumor growth, 
when it binds to methylated CpG sites. In their study the levels of cells in G1 phase were 
measured by using flow cytometry and the cancerous and non-cancerous cell lines were 
compared in Cell Quest software, before and after Kaiso knockdown. In the cancerous cell 
lines, the Kaiso protein was knockdown by siRNA, which led to a reduction of cancer cells in 
G1 phase compared to non-cancerous cells, thus indicating that Kaiso facilitates 
tumorigenesis [Lopes et al., 2008].  
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As mentioned, miRNAs can function as TSGs and oncogenes. A study performed by Yan and 
colleagues (2011) showed that 64 miRNAs were methylated in CRC cell line (HCT116). The 
results were obtained by comparing 5’-Aza-2’-deoxycytidine treated cells with untreated 
cells. The treated cells showed less migration and invasion compared to the untreated cells 
[Yan et al., 2011]. The results demonstrated the importance of miRNA and the effect 
epigenetic alterations have.  
 
Epigenetic alterations have been demonstrated to be important in regard to cancer, both as 
prognostic markers, but also to diagnose cancer such as CRC and determine treatment 
[Coppedé, 2014]. Epigenetics are thus very useful since it can be used as biomarkers. Many 
biomarkers are found, and some used, to clarify the stage, diagnose and prognoses [Coppedè, 
2014]. The treatment is likewise decided based on epigenetic findings because of their 
eventual interactions with the chemotherapeutic reagents, which can lead to chemoresistance 
[Coppedè, 2014]. 
Numerous studies have shown that CGI promoter methylation is cancer-specific [Berdasco & 
Esteller, 2010; Esteller et al., 2001; Ehrich et al., 2008]. One study was performed by Esteller 
and colleagues (2001), which demonstrated that human cancer has a unique profile of 
promoter hypermethylation. In the study they investigated genes known to be silenced due to 
epigenetic alterations as seen for TSGs, DNA repair genes and genes affecting metastasis and 
invasion. Their result is shown in figure 13, where the colors illustrates the different genes 
investigated. The height of the columns illustrates the frequency of hypermethylation [Esteller 
et al., 2001]. 
 
Figure 13: Promoter hypermethylation profiles in cancer – The different types of cancer have unique profiles 
in regard to promoter hypermethylation. For each cancer type, the epigenetics modifications of multiple genes 
were investigated. The colors represent different genes and the height of the columns illustrates the frequency of 
the hypermethylation [Esteller et al., 2001]. 
The study showed that some genes are hypermethylated in almost all of the tumor types, as 
seen for the cell cycle inhibitor gene p16 (dark blue). Others are specific for a tumor type, as 
Genes 
Tumor	  types 
Frequency	  of	  
Hypermethylation 
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is the case with BRAC1 (light blue) and CDH1 (purple). Lastly, some are restricted to 
sporadic tumor types, as is the case with the previously mentioned hMLH1 (green) [Esteller et 
al., 2001]. 
These unique profiles could work as a marker system for detection of cancer in different 
stages and to predict the effect of some chemotherapeutic drugs.  
 
The theory mentioned this far enables an understanding of the field of epigenetics and will be 
used to investigate the chosen genes – The N-Myc downstream-regulated genes.  
 
2.3 N-Myc downstream-regulated gene 
MYC is a proto-oncogene that functions as a regulatory gene [Dang, 2012]. The gene encodes 
a transcription factor, function as a switch for several cellular processes, which regulates cell 
behavior e.g. growth, proliferation and differentiation [Dang et al., 2009; Yao et al., 2008; 
Vervoorts et al., 2006]. The family of MYC consists of lung carcinoma-derived MYC (L-
MYC), N-MYC and cellular-derived MYC (C-MYC). The MYC family regulates multiple 
genes of which NDRG is one [J. Zhang et al., 2006].  
 
The NDRG family exists in many multicellular species where they are relatively conserved 
indicating that the proteins are important [Yang et al., 2013]. In mammals there are four types 
NDRGs: NDRG1-4, which are involved in cellular development, differentiation, proliferation, 
migration and in stress response [Melotte et al., 2010; Yao et al., 2008]. The four types all 
have different functions in the body and are expressed at different levels in the different 
tissues [R. H. Zhou et al., 2001; Lorentzen et al., 2011]. The four members have 57-65 % 
amino acid sequence homology, but none of the four types has a clear functional peptide 
motif [Melotte et al., 2009; Yao et al., 2008]. The NDRG proteins share two characteristic 
regions: a NDR- and an α/β-hydrolase-fold region. The biggest differences in the family are 
within the N- and C-terminal regions as illustrated in figure 14 [Melotte et al., 2010].  
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Figure 14: N-Myc downstream-regulated (NDRG) family - This family of genes is characterized by their NDR-
domain and α/β hydrolase-fold regions [Melotte et al., 2010] 
NDRGs have many function in the body e.g. cellular differentiation and stress respond and 
therefore they have been implicated in various diseases, e.g. Alzheimer [Melotte et al., 2010; 
Mitchelmore et al., 2004].  
The family is divided into two groups due to their homology, placing NDRG1 and NDRG3 in 
one group and NDRG2 and NDRG4 in another. This is due to their 67 % and 58 % homology, 
respectively [Yang et al., 2013]. 
 
All of the NDRG genes have been implicated in cancer due to epigenetic alteration, which 
have either up- or down-regulated the genes. Their alteration and effect in CRC is shown in 
table 1. 
 
Table 1: Epigenetic alteration for the NDRG family in CRC 
Gene Alteration Effect/method Reference 
 
NDRG1 
Up-regulated 
 
 
Down-regulated 
Cell cycle and pro-
liferation 
 
Expression is decreased in 
adenomas and adeno-
carcinomas and metastatic 
colon cancer 
 
240 clinical CRC tissue 
 
Metastatic-suppressor 
 
High level correlates with 
Yang et al., 2013 
 
 
Melotte et al., 
2010 
 
 
 
Mao et al., 2013 
 
Guan et al., 2000 
 
Shah et al., 2005 
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low stages 
 
NDRG2 
Up-regulated 
 
Down-regulated 
- 
 
Cell cycle 
 
Silencing increased pro-
liferation in vitro 
 
Methylation of NDRG2 
correlates with cancer 
stage 
 
 
High NDRG2 mRNA 
level correlates with 
better prognosis 
- 
 
Yang et al., 2013 
 
Melotte et al., 
2010 
 
Piepoli et al., 2009 
Lorentzen et al., 
2007 
Kim et al., 2009 
 
Chu et al., 2011 
NDRG3 Up-regulated 
Down-regulated 
- 
- 
- 
- 
NDRG4 Up-regulated 
 
Down-regulated 
- 
 
Cycle arrest 
 
Overexpression reduced 
proliferation and invasion 
in vitro. High methylation 
in promoter region 
correlates with advanced 
CRC stages 
 
NDRG4 suppress 
apoptosis 
- 
 
Yang et al., 2013 
 
Melotte et al., 
2009 
 
 
 
 
 
Wilson et al., 2010 
 
 
2.3.1 NDRG1	  
NDRG1 was the first member to be discovered in the NDRG family and is located at 
chromosome 8q24.3 and codes for a 3 kb mRNA [Yang et al., 2013].  
Shimono and colleagues (1999) discovered NDRG1 by analyzing N-MYC knockdown mice. 
Here they subtracted cDNA from the N-MYC deficient mutant mice and compared it to the 
wild type. This revealed Ndrg1, which was regulated by N-MYC [Shimono et al, 1999; J. 
Zhang et al., 2008]. Lachat and colleagues (2002) showed with the use of immunohisto-
chemistry that NDRG1 mRNA is present in most human tissues, but the level of mRNA 
varies from tissue to tissue and is reported to be higher in certain organs e.g. in the small 
intestines [Lachat et al., 2002].  
To elucidate the function of NDRG1 a Ndrg1 knockout study was performed on mice, which 
demonstrated that Ndrg1-deficient mice had muscle weakness as a result of demyelination of 
the peripheral nerve [Okuda et al., 2004].  
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NDRG1’s role in cancer has been studied for many years and some studies conclude that the 
NDRG1 expression, both at mRNA and protein level, is decreased in e.g. CRC, but in other 
types e.g. cervical cancer, the levels are found to be up-regulated compared to normal cells. 
This leads to the conclusion that the role of NDRG1 is tissue-specific [Cangul et al., 2002; 
Melotte et al., 2010].  
 
Mao and colleagues (2013) investigated the effect of NDRG1 in CRC. In the study, 240 
clinical CRC tissue samples were used and compared with their paired non-tumorous 
counterpart.  The comparison showed that the level of NDRG1 mRNA and protein were 
decreased in CRC [Mao et al., 2013]. A study performed by Guan and colleagues (2000) 
demonstrated that NDRG1 is epigenetically regulated. This was illustrated by treating CRC 
cell lines e.g. SW480 with histone deacetylation inhibitor (HDACi) and DNA methylation 
inhibitors, which led to an increased level of NDRG1. Next, they demonstrated NDRG1’s 
effect on metastasis by comparing two types of CRC cell line; a primary (SW480) and a 
metastatic CRC (SW620), and showed that the NDRG1 level was down-regulated in SW620. 
Finally, NDRG1 was overexpressed in nude mice, which led to metastatic suppression 
without affecting the primary tumor. Thus NDRG1 also participates in metastatic suppression 
[Guan et al., 2000]. The epigenetic regulation of NDRG1 was further elucidated by Zhang and 
colleagues (2008), who demonstrated that NDRG1 is down-regulated due to MYC binding on 
the NDRG1 promoter [J. Zhang et al., 2008].  
 
Studies of the role of NDRG1 in cancer have shown contradictory results. In some tissues it 
has been demonstrated to have a tumor suppressive role e.g. in the brain, breast and colon, 
whereas in other tissues it has an oncogenic role e.g. in the kidney, liver, skin and skin [Fang 
et al., 2014]. The different roles of NDRG1 has been shown to correlate with different 
microenvironment of a given cancer type. This is seen for prostate cancer, where the level of 
NDRG1 can be affected by hypoxia and androgen receptors [Fang et al., 2014; Melotte et al., 
2010].  
Lastly, Shah and colleagues (2005) compared different stages of CRC, which demonstrated 
that NDRG1 expression might be associated with aggressiveness of the tumor. The study 
consisted of samples from 131 patients and by performing immunohistochemistry, the authors 
showed that high expression of NDRG1 was associated with early stages of cancer, indolent 
metastasis, but also resistance of chemotherapy. Thus the level of NDRG1 protein is 
associated with less aggressive tumors and can thereby be used to predict treatment types 
[Shah et al., 2005]. 
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2.3.2 NDRG2	  
NDRG2 is located at chromosome 14q11.2 and codes for two isoforms due to alternative 
splicing. One contains 371 amino acids and the other 357 amino acids [Yang et al.. 2013]. 
The NDRG2 protein exists primarily in the cytoplasm, but has also been detected in the cell 
membrane, adherens junctions and nucleus, when the cell is under stress [Yao et al., 2008]. A 
bioinformatical analysis of NDRG2 revealed binding sites for various transcription factors 
that are involved in growth regulation. In the human body NDRG2 has been shown to have 
multiple functions e.g. in cellular differentiation, stress response and in apoptosis [Yao et al., 
2008; N. Liu et al., 2008; Y. J. Kim et al., 2009].  
The regulation of the NDRG2 has been studied in mice, due to the high similarity of Ndrg2 
and NDRG2, but the study could not connect the Ndrg2 down-regulation with MYC, as seen 
for NDRG1 [J. Zhang et al., 2006; Shimono et al., 1999]. A study performed by Zhang and 
colleagues (2006) showed that the regulation of human NDRG2 depended on the Myc-
interacting zinc finger protein 1 (Miz-1). This was demonstrated in various human cell lines 
e.g. HEK293, where interaction of NDRG2, MYC and Miz-1 was demonstrated by ChIP 
assays. The link between NDRG2 and MYC was demonstrated by a co-transfection, 
illustrating that Miz-1 affected MYC. Lastly, they tested whether NDRG2 repression by MYC 
required HDAC activity by treating the cells with HDACi. This reduced the NDRG 
repression, indicating that HDAC is required for MYC repression of NDRG2. Thus Miz-1 is 
required for MYC repression of NDRG2 in humans, probably by the recruitment of HDAC [J. 
Zhang et al., 2006]. 
 
NDRG2’s role in cancer has also been studied. NDRG2 mRNA and protein levels are 
decreased in many types of cancer [N. Liu et al., 2007]. Lorentzen and colleagues (2011) 
studied the levels of NDRG2 mRNA in different cancer types by comparing them with 
healthy tissues. This demonstrated that the level of NDRG2 mRNA was decreased at least 
two-fold in many of the cancer types investigated e.g. CRC [Lorentzen et al., 2011]. Piepoli 
and colleagues (2009) performed series of studies, where they also demonstrated down-
regulation and promoter methylation of NDRG2, both in CRC cell lines and in CRC patient 
samples. The cell lines, HCT116, SW480 and CaCo2 were used to identify hypermethylated 
genes by comparing HDACi treated and untreated cell lines, of which NDRG2 was identified. 
Next, the promoter regions of NDRG2 in the cell lines were analyzed along with 30 patient 
samples, which consisted of CRC tissues and their paired healthy tissues. This revealed that 
the cell lines were hypermethylated compared to healthy colon samples, but only 27 % of the 
30 patient samples were hypermethylated. Further, Piepoli and colleagues found that NDRG2 
was more highly methylated in the advanced stages of CRC [Piepoli et al., 2009]. The 
correlation between the stages of CRC and level of methylation was independently 
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demonstrated both by Lorentzen and colleagues (2007) and by Kim and colleagues (2009). 
Both studies used CRC patient samples and compared them with their paired healthy mucosal 
tissues. As mentioned, this demonstrated that the level of NDRG2 decreased in the more 
advanced CRC stages [Lorentzen et al., 2007; Y.-J. Kim et al., 2009]. Therefore, the 
methylation level of CRC can be used as a prognostic mark. Chu and colleagues (2011) also 
demonstrated that the NDRG2 mRNA level could be used as a prognostic mark because 
patients with a high level of NDRG2 mRNA had better prognosis [Chu et al., 2011].  
Lastly, Feng and colleagues (2011) demonstrated that miRNA also regulates NDRG2 in CRC. 
This was demonstrated by a luciferase assay on miRNA transfected cell lines (SW480, HT29, 
LoVo and SW620), which demonstrated that an up-regulation if miRNA (miR-650) 
correlated with a decrease in NDRG2 levels [Feng et al., 2011].  
 
Many studies have further investigated the role of NDRG2 and have concluded that NDRG2 
has a tumor suppressive role in cancer and that it may be a biomarker for the identification of 
cancer [Melotte et al., 2010; Yao et al., 2008]. 
 
2.3.3 NDRG3	  
The NDRG3 gene is located on chromosome 20q11.21-11.23 and encodes a 363 amino acids 
protein mostly found in the nucleus [Yang et al., 2013; Yao et al., 2008].  
Zhao and colleagues (2001) investigated the expression pattern for NDRG3 by northern 
blotting and demonstrated that NDRG3 is primarily detected in prostate, testes and ovary. For 
the tested testis-mRNA, NDRG3 showed two bands, which indicates an alternative splicing of 
NDRG3 [Zhao et al., 2001]. NDRG3 is therefore believed to play a role in spermatogenesis 
since NDRG3 mRNA is found in the outer layer of the seminiferous epithelium [Yang et al., 
2013]. To elucidate the function of NDRG3, null-mice have been generated, but the pups died 
early in embryogenesis [Berger & Bird, 2005]. Therefore it has been concluded that NDRG3 
is important for development. 
 
The investigation of NDRG3 in regard to cancer has been limited [Yang et al., 2013]. 
However, studies have demonstrated that NDRG3 has an oncogenic effect when 
overexpressed in nude-mice [Melotte et al., 2010].  
Wang and colleagues (2009) demonstrated that NDRG3 is a tumor promoter in prostate 
cancer in an overexpression study. The study was performed with prostate cell line (PC-3), 
which showed increased growth rates and migration abilities compared to non-treated cells. 
Further, they demonstrated that NDRG3 contributes to angiogenesis by up-regulating 
chemokines [Wang et al., 2009]. 
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2.3.4 NDRG4	  
The NDRG4 gene is located on chromosome 16q21-22.1 and is believed to play a role in 
neural differentiation [Yang et al., 2013]. A study conducted by Zhou and colleagues (2001) 
elucidate the expression of NDRG4. The study showed three different isoforms of NDRG4: 
NDRG4-B, NDRG4-Bvar, and NDRG4-H, all arising due to alternative splicing. The study 
further demonstrated that NDRG4 is expressed in brain and heart, and that NDRG4-B and 
NDRG4-Bvar only in the brain [Zhou et al., 2001]. Yamamoto and colleagues (2011) 
generated NDRG4-deficient mice to reveal the role of NDRG4 in the brain. The study 
demonstrated that mice had impaired memory and learning abilities, but normal motor 
function. Further, the levels of e.g. brain-derived neurotropic factor (BDNF) were decreased, 
which are necessary for learning and neural homeostatic. Thus it was concluded that NDRG4 
is important for maintenance of BDNF in the brain, which correlates to learning and memory 
in mice [Yamamoto et al., 2011]. 
 
The investigation of NDRG4 in cancer development has been sparse [Yang et al., 2013]. A 
study performed by Melotte and colleagues (2009) showed that NDRG4 is a TSG and that the 
gene becomes inactivated due to promoter methylation in CRC. The study was performed on 
CRC cell lines and tissues obtained from CRC patients, which were compared to tissues from 
healthy patients. The CRC cell lines were used to establish the promoter status, which showed 
that they were methylated in 7/8 of the cell lines (HCT118 was, SW480 was not). For the 
patient samples, 4 % of the control samples were methylated compared to 86 % of the CRC 
samples. The investigation of patient samples also revealed that the NDRG4 promoter level 
was more frequently methylated in advanced CRC and that the levels of NDRG4 mRNA and 
protein decreased in CRC compared to normal colon mucosa [Melotte et al., 2009]. 
Melotte and colleagues (2009) also performed an overexpress study of NDRG4. 
Overexpression of NDRG4 in CRC cell line resulted in a decreased level of proliferation, 
colony formation and invasion [Melotte et al., 2009]. Thus NDRG4 is a TSG in CRC and it is 
inactivated by promoter methylation [Melotte et al., 2009; Yang et al., 2013]. 
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3 Experiment	  
The experiment of this thesis was divided into five main parts starting with quantifying the 
mRNA of each NDRG genes followed by examination of their methylation status. Next MBPs 
expression was investigated at mRNA and protein level and their interactions with methylated 
DNA were likewise investigated. Finally, RNAi was used to analyze the MBP’s effect on the 
NDRG genes. All the experiments  
3.1 Materials and methods 
3.1.1 Cells	  
Four different human cancer cell lines were used: HCT116, DLD-1, SW480 and LoVo. The cells 
were grown in T75 flasks with McCoy 5A medium (#16600-082 from Life technologies) with 
10 % fetal bovine serum (# F0804 from Sigma) and 0.1 % Penicillin/Streptomycin (P/S) 
(#P0781 from Sigma). This will from now on be referred to as McCoy medium.  
The cells were kept in an incubator with a constant temperature at 37 °C and 5 % CO2.  
 
All the cell lines are collected from adult males, around 50 years old, with CRC [ATTC| (n.d.)], 
see table 2. HCT116, DLD-1 and SW480 are derived from primary colon cancer lesions, while 
LoVo is derived from a metastatic lesion of colon cancer [Guan et al., 2000]. 
 
Table 2: CRC cell lines  
 Disease 
[ATTC| (n.d.)] 
Differentiated 
[Niu et al., 2012] 
Lesion 
[Guan et al., 2000] 
HCT116 Colorectal cancer (Carcinoma) Poorly Primary CRC 
DLD-1 Colorectal cancer (Dukes type C) - Primary CRC 
SW480 Colorectal cancer (Dukes type B) Moderately Primary CRC 
LoVo Colorectal cancer (Dukes type C) Poorly Metastatic CRC 
 
3.1.1.1 Cell	  subculturing	  
All cell work was done in a laminar flow cabinet  (LAF) bench. The cells were subcultured 
when they reached a confluence of 80 % by removing the old McCoy medium by aspiration. 
This was followed by washing with 10 mL PBS (1.4 M NaCl, 27mM KCl, 101 mM Na2HPO4, 
18 mM KH2PO4) and trypsinization with 1 mL trypsin (#T3924 from sigma) for 5 minutes at 
37°C. After the 5 minutes, 9 mL McCoy medium were added and the cells were resuspended in 
the medium. Subsequently, 1 mL of the cell suspension was transferred to a new T75 flask and 
14 mL new McCoy medium was added. The flask was incubated in at 37°C in an incubator.  
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3.1.2 Quantification	  of	  NDRG	  genes	  	  
Quantification of the mRNA was completed with the housekeeping gene RPLP0 as the reference 
gene.  
3.1.2.1 RNA	  isolation	  
When isolating RNA, the samples were stored on ice at all time and processed under a fume 
hood, which was pre-cleaned with RNaseZAP (#R2020 from Sigma).  
Before the RNA could be isolated from the cells, the cells were harvested followed by 
centrifugation, frozen in TRI REAGENT (#AM9738 from Applied Biosystems) and stored over 
night (O.N.) at -80°C. The next day the cell pellet was thawed on ice and resuspended. 0,1 mL 
chloroform (#67-66-3 from MERCK) was added to each of the tubes, vortexed for 15 seconds 
and left at room temperature (RT) for 10 minutes. During this time three phases became visible. 
The sample was centrifuged for 10 minutes at 12,000g and the upper RNA phase was collected 
in a new 1.5 mL eppendorf tube. 0.25 mL isopropanol (#67-63-0 from MERCK) were added to 
the new tubes, vortexed and left for 5 minutes at RT. Finally, it was centrifuged for 10 minutes 
at 12,000g and stored at -20°C O.N.. 
The following day, the samples were thawed on ice and centrifuged for 20 minutes at 12,000g at 
4°C and the concentration were measured at 260 nm on NanoDrop® Spectrophotometer ND-
1000. The RNA samples were stored at -80°C and were then ready for use. 
 
3.1.2.2 cDNA	  synthesis	  
For the synthesis of cDNA the kit ‘High capacity cDNA reverse transcription kit’ (#4368814 
from Applied BioSystem) was used. A mastermix was made according to the manufacture’s 
protocol, consisting of 10x RT buffer, 25x dNTP mix, 10x Random primer, multiscribeTM 
reverse transcriptase, and nuclease free H2O, as seen in table 3. The sample was incubated in the 
thermal cycler. 
 
Table 3: cDNA synthesis mastermix according to ‘High capacity cDNA reverse transcription kit’ (#4368814 
from Applied BioSystem) protocol. 
10x RT buffer 2.0 µL 
10x Random buffer 2.0 µL 
25x dNTP mix 0.8 µL 
MultiscribeTM reverse transcriptase 1.0 µL 
H2O 4.2 µL 
RNA 1.0 µL 
Total volume 11.0 µL 
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Each reaction requires 1 µg RNA per 10 µL mastermix. The thermal cycler was set to 25°C for 
10 minutes, 37°C for 120 minutes, 85°C for 5 seconds, and paused at 4°C. The cDNA samples 
were stored at -20°C. 
3.1.2.3 Quantitative	  polymerase	  chain	  reaction	  
Quantitative PCR (qPCR) is a method used to determine the amount of a target gene or sequence 
[Life Tecnologies, n.d.]. To perform qPCR the kit ‘QuantiTect® SYBR® green PCR (#204141 
from Qiagen)’ was used. According to protocol a mastermix was made with cDNA and samples 
were processed on the qPCR machine (Stratagene MX3005P from AH Diagnostics). 
The mastermix consisted of 2x QuantiTect-SYBR® green, a forward and a reverse primer, 
nuclease free H2O and cDNA template in the ratio as described in table 4. 
 
Table 4: The mastermix was done according to ‘QuantiTect® SYBR® green PCR’ (#204141 from Qiagen) 
protocol 
2x QuantiTect-SYBR® green 5.0 µL 
Primer 1 (forward) 1.0 µL 
Primer 2 (reverse) 1.0 µL 
H2O 2.0 µL 
cDNA 1.0 µL 
Total volume 10.0 µL 
 
The thermal profile consists of three segments as illustrated in figure 15. The first segment is the 
‘hot-start’ segment, while the second segment is the annealing and elongation part, as seen in 
conventional PCR. In this part a measurement is obtained in each cycle-end, which measures the 
relative amount of the target gene. Lastly, the third segment measures the dissociation of the 
product to determine the melting temperature to make a dissociation curve [Applied Biosystems, 
n.d.]. The thermal profile was set to 95°C for 15 minutes in the first segment and 95°C for 15 
seconds, 52°C for 15 seconds, 72°C for 30 seconds in the second segment. The first segment 
was 1 cycle, while the second segment was set to 45 cycles. The last segment was set to 95°C 15 
seconds, 55°C for 30 seconds and 95°C for 30 seconds, which also was 1 cycle. 
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Figure 15: qPCR program – The first segment is a hot-start phase, which activates the SYBR® green. The second 
segment is the annealing and elongation phase, as with conventional PCR. The last segment creates a dissociation 
curve. This picture illustrates the program for RPLP0. 
 
In the plate setup, the dyes FAM and ROX were chosen. The FAM dye detects the SYBR® 
green dye, which binds to double stranded DNA while the ROX was used as the reference dye. 
The labels ‘unknown’, ‘no RT’, and ‘NTC’ were given respectively to the samples with reverse 
transcriptase, without reverse transcriptase, and no template control (H2O). 
 
A standard curve was first obtained by making a dilution series consisting of undiluted cDNA, 
5x, 25x, 125, 625x, 3125x and 15,625x diluted cDNA. The dilutions were run in duplicates on 
the qPCR machine, which gives an automatic threshold value, it can however be regulated to fit 
the samples to give the best efficiency. The obtained threshold can then be used for unknown 
samples. All unknown samples were  run in triplicates. 
 
3.1.3 Methylation	  status	  of	  the	  NDRG	  genes	  
3.1.3.1 DNA	  isolation	  
For DNA isolation the laboratory’s protocol ‘Standard DNA extraction’ was used. This required 
a mix of 600 µL TENS buffer (100 mM,TrisCl, 5 mM EDTA,200 mM NaCl, 0.2 % SDS) and 
7.5 µL ProteinaseK. 
 
For each sample, 500 µL of the mix was transferred to a 1.5 mL eppendorf tube, which was put 
on a 55°C heat-block with agitation (900 rpm) O.N.. 
The next day the samples were removed from the heating block and cooled down to RT. After 
they had were cooled, they were vortexed at maximum speed (13,400 rpm) for 15 seconds and 
centrifuged for 5 minutes at 12,000 rpm at 15°C. 500 µL isopropanol were added to new tubes 
and the supernatant from the centrifuged samples was transferred to the newly marked tubes. 
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The tubes stood for 5 minutes and were inverted a couple of times and were then again 
centrifuged under the same conditions. The supernatant was transferred to new tubes and 
afterwards washed in 80 % ethanol and centrifuged at the same conditions as before. The 
supernatant was added to the newly marked tubes and air-dried for 7 minutes. 100 µL TE buffer 
(10 mM Tris-HCl, 1 mM EDTA) were added to each of the tubes and put back on the 55°C 
heating block with agitation (900 rpm) until the pellet was dissolved. The samples were stored at 
-20°C. 
 
3.1.3.2 Bisulfite	  treatment	  
Bisulfite treatment is used to examine the methylation status of specific regions of the DNA and 
was performed on all the four cell lines, human genomic DNA (#11691112001 from Roche 
Diagnostiks) and methylated genomic DNA (#MO2265 from BioLabs). To methylate the 
genomic DNA it was treated with S-adenosylmethionine (SAM) (#B90035 from BioLabs), 
which functions as a positive control (PC) for methylation and untreated genomic DNA 
functions as a negative control (NC). 
 
The bisulfite treatment consist of three steps: a sulfonation, a deamination and a desulfonation as 
illustrated in figure 16 [Pappas et al., 2009]. In the first step, HSO3- is added across the 5,6-
double band, which is hindered when the cytosine is methylated. The second step is the 
deamination of NH3 through hydrolysis and step three is the release of HSO3- to form uracil 
[Hayatsu, 2008]. 
 
Figure 16: Bisulfite treatment – Bisulfite treatment is a technique used to determine DNA methylation by converting 
unmethylated cytosine to uracil. The conversion is done over three steps where HSO3- is added to the 5,6-double band 
in the first step followed by hydrolysis, which leads to the removal of NH3, ended by the release of NH3 to form uracil 
[Hayatsu, 2008]. Modified from [Darst et al., 2010].   
The kit ‘BisulFlash™ DNA modifications Kit’ (#P-1026-050 from Epigentek™) was used to 
bisulfite treat DNA. The kit had containers named BF1-BF6, see table 5. 
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Table 5: BisulFlash™ DNA modifications Kit contents 
 Function 
BF1 Conversion Mix 
Solution 
BF2 Capture Solution 
BF3 Desulfonation Solution 
BF4 Elution Soultion 
BF5 Conversion Enhancer 
BF6 Denaturation Enhancer 
 
First 1 mL of BF1 was added to BF5 and was inverted and shaken for 5 minutes or until the BF5 
dissolved. The 80 µL of BF6 were added to BF5 and it was also inverted and shaken. 110 µL of 
the BF5/BF1/BF6 mix and 200 ng DNA were added to 0.2 mL PCR-tubes. This was run on a 
thermal cycler for 20 minutes at 95°C. 250 µL BF2 were added to each of the columns and a 
mixture of 10 µL BF3 and 0.8 mL 90 % ethanol was mixed in a 1.5 mL eppendorf tube.  
The PCR-product was then added to the columns and centrifuged for 30 seconds at 12,000 rpm. 
The fluid in the collection tube was discarded and the pellet was afterwards washed with 200 µL 
90 % ethanol and centrifuged at 20 seconds at 12,000 rpm. 60 µL of the BF3/90 % ethanol mix 
were added and incubated for 8 minutes at RT. Next, it was centrifuged as before and washed 
twice with 200 µL 90 % ethanol. Lastly, the columns were transferred to new collection tubes 
and 20 µL of BF4 were added to each column and centrifuged for 30 seconds at 12,000 rpm. The 
samples were stored at -20°C. 
 
3.1.3.3 Sequencing	  of	  bisulfite	  treated	  cell	  lines	  
Sequencing was performed to determine the methylation status of the NDRG genes in the cell 
lines. By using the program MethPrimer [MethPrimer⎥Li Lab, UCSF,” n.d.] CpG islands were 
predicted and bisulfite-specific primers were designed in CpG-rich regions for NDRG1, 
NDRG3, and NDRG4 (see appendix 9.3.1 figure 47). The primers were used to perform a PCR 
reaction, which was run on a 1 % agarose gel (100 µL 1xTBE buffer (10x #15581-044 from 
Gibco)+ 1g agarose (#9012-36-6 from Sigma)) to which 10 µL ethidium bromide (#200 271 
from Boehringer Mannheim) was added.  
 
3.1.3.3.1 Polymerase	  chain	  reaction	  
The PCR reaction was performed to validate the presence of the NDRG genes in the four cell 
lines prior to sending the samples to sequencing in Eurofins Genomics A/S. A mastermix 
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consistent of Maxima Hot-start, primers, template and H2O was done according to the Maxima 
Hot-start PCR mastermix (2x) (#K1051 from Thermo Scientific) protocol as seen in table 6. 
 
Table 6: PCR mastermix according to Maxima Hot-start protocol for one reaction. 
Maxima Hot-start 7.5 µL 
Forward primer 1.0 µL 
Reverse primer 1.0 µL 
 
Template (cDNA) 2.0 µL 
H2O 3.5 µL 
Total 15.0 µL 
 
The samples were put in a thermal cycler (Biometra® T3000) and run at 95°C for 4 minutes 
followed by Y cycles of 95°C for 30 seconds, X°C for 30 seconds, 72°C for 30 seconds and 
finally 1 cycle of 72°C for 5 minutes and 4°C until use. 
The X and Y changes accordingly to the specific primer set and refers to the annealing 
temperature and the number of cycles, respectively (see appendix 9.3). 
4 µL loading buffer was added to the PCR product and run with a 7.5 µL of 1 kDa ladder (#1333 
from Thermo Scientific) on a 1 % agarose gel. 
 
The bands on the gel were cut out under a 360 nm UV light and separated into pre-weight 2 mL 
eppendorf tubes, which afterwards were weighed again to calculate the weight of the agarose. 
300 µL isopropanol were added per 100 mg agarose gel and mixed vigorously for 30 seconds 
followed by 10 minutes incubation at 56°C on the heating block. Next, 150 µL 80 % ethanol 
were added per 100 mg agarose gel and vortexed as before. The solution was transferred to 
collection tubes that contained ‘High pure filter tubes’ and centrifuged at 13,400 rpm for 60 
seconds. The flow-through was discarded, 500 µL wash buffer were added and the samples were 
centrifuged under the same conditions. The flow-through was discarded and the sample was 
likewise washed with 200 µL wash buffer. 30 µL of TE-buffer were added, incubated for 1 
minute and centrifuged at 13,400 rpm for 1 minute. Each of the samples were measured by 
nanodrop and the samples were stored at -20°C. 
 
The sequencing was done in Germany at Eurofins genomic A/S and sent accordingly to the 
company protocol: 30 µg (15 µL) of the PCR product along with 2 µL primer. 
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3.1.4 MBPs	  expression	  on	  mRNA	  and	  protein	  level	  
3.1.4.1 mRNA	  detection	  
To detect the mRNA of the MBPs, PCR was performed as described above. The PCR product 
was run on a 1 % agarose gel with 7.5 µL 1 kDa ladder (#1333 from Thermo Scientific). 
 
3.1.4.2 Protein	  isolation	  
For protein isolation the laboratory’s protocol ‘Whole cell extraction’ was used. 
This required a lysis buffer++ consisting of 1 mL RIPA450 (10 mL 10xPBS, 1.8 g NaCl, 1 mL 
polyethyleneglycol-p-isoctyphenyl ether NP-40, 1mL 10 % SDS, 0.5 sodium doxycholate, 100 
µL 0.5 M EDTA (pH 8.0), and 88 mL H2O), 2 µL 0.5 M Dithiotretiol (DTT) (#3483-12-3 from 
Fluka) and 2 µL protease inhibitor (#P8340 from Sigma).  
30 µL of the buffer was added to each of the samples and then homogenized 5 times with a 
Pellet Pestle motor (from Kontes). The samples were incubated at RT for 30 minutes and 
centrifuged at 4°C for 10 minutes at 12,000g. The supernatant was transferred to a new 1.5 mL 
eppendorf tube and centrifuged by the same conditions. The supernatant was transferred to a 
new tube and the protein content was measured by use of Bradford Reagent. The samples were 
stored at -80°C. 
 
3.1.4.3 	  Bradford	  protein	  assay	  
Bradford protein assay was used to measure the protein content. 1 mL of Bradford reagent was 
added to a curvet with 2 µL of the protein sample. As a blank 2 µL of RIPA450 buffer were 
used. The mix was incubated for 10 minutes at RT in the dark. The samples were pipetted up 
and down and measured with a BioPhotometer, which measures the wavelength at 590 nm. 
  
3.1.4.4 Western	  Blot	  
Western blotting was used to detect the protein content with the use of antibodies, to elucidate if 
the MBPs were detectable on protein level. The different buffers required to make western blots 
are listed in table 7 below and all antibodies used are listed in appendix 9.4.  
 
The protocol required 10-30 µg proteins and 15 µg were loaded. To the protein samples 1.5 µL 
0.5 M DTT and 3.75 µL NuPage LDS sample buffer (4X)(#NP0007 46-5030, Invitrogen™) 
were added and the solution was incubated at 70°C for 10 minutes. The entire sample solution 
was loaded along with a 1 kDa ladder (#26616, Thermo Scientific) to the gel (NuPage 4-12 % 
Bis-Tris gel #NP0322BOX, Invitrogen™). Afterwards the gel was put in the XCell II™ Blot 
module (Invitrogen™), covered with running buffer and run at 120 V.  
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Filters and PVDF transfer membrane (#RPN303F, Amersham Hybond™-P) were cut in required 
sizes, the blotting pads were soaked in Bis-Tris transfer buffer and the air was pushed out. The 
PVDF membrane was soaked in ethanol 96 % for 30 seconds, washed in H2O and kept in Bis-
Tris transfer buffer until use. 
After the gel had run, the transfer of the protein to a PVDF membrane was assembled as 
according to figure 17A. The SDS machine was set to run at 25 V for 1 hour and 15 minutes. 
The blot was removed and put in a fitting box and stained with 10 mL of ponceau red for 15 
minutes, which colored the proteins as seen in figure 17B.  
 
 
Figure 17: Western blot – A) Assembling of western blot. From cathode core and up: Blotting pads, soaked in 
transfer buffer, followed by filter paper, the gel and the transfer membrane. Next, a filter paper is added followed by 
blotting pads. B) PVFD membrane, stained by ponceau red showing all the proteins loaded on the blot [Invitrogen, 
2009]. 
The red color was removed by washing the blot with 5 % acidic acid (#K38772163 from 
MERCK). The PVDF membrane was separated and incubated with gentle agitation for 20 
minutes with blocking buffer (se table 7) and then washed by 2x 2 minutes with wash buffer. 
The primary antibody was added to the dilution buffer and transferred to the membrane and 
incubated at 4°C O.N. (see antibodies in appendix 9.4). After the dilution buffer was removed 
and the membrane was washed 2x 10 minutes with wash buffer. The secondary antibody (anti-
mouse #1858413 or anti-rabbit #1858415 from Pierce) was likewise diluted and incubated for 1 
hour with gentle agitation. The membrane was washed 4x 10 minutes with wash buffer followed 
by 5 minutes incubation at RT in the dark with Pierce Dura detection (#34076 from Sigma). 
Finally, the blot was developed with the BioSpectrum ® AC Imaging system.  
 
Table 7: Buffers for western blot 
Buffer Contain 
Tris-Bis transfer 
buffer 
50 mL 20x transfer buffer (#NP0006-1 from Life technologies) 
208 mL 96 % ethanol 
742 mL H2O  
Tris-Bis running 
buffer 
50 mL 20x NuPage MOBS buffer (#NP00001 from Life 
technologies) 
950 mL 
Wash buffer (PBS-T) 1 L PBS (1.4 M NaCl, 27 mM KCl, 101 mM Na2HPO4, 18 mM 
A B 
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KH2PO4) 
1 mL Tween-20 (#9005-64-5 from Sigma) 
Blocking buffer 20 mL PBS-T  
1 g infant formula 
Dilution buffer 20 mL PBS-T 
0.5 g infant formula 
 
 
3.1.5 Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed on the cell extract for all the CRC cell 
lines, to verify if the MBPs interact with the chromatin of the NDRG family. 
When the cell lines were 80 % confluent, they were treated with 937.5 µL 16 % formaldehyde 
(#18814 from Polysciences) and 2 mL 1M glycine (#56-40-6 from MERCK) in the LAF bench 
and incubated with agitation for 10 and 5 minutes, respectively. The medium was removed with 
a Pasteur pipettes and washed twice with 10 mL cold PBS. The cells were removed manually 
from the T75 flask with a cell scraper (25 cm from Sarstedt) over two times, first with 5 mL cold 
PBS, then with 3 mL cold PBS. The content was transferred to a 15 mL tube, which was 
centrifuged 5 minutes at 1000g and the supernatant was removed.  
To lysate the cells, 750 µL ChIP lysis buffer (50mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1 
mM EDTA (pH 8), 1 % Triton X-100, 0.1 % sodium deoxycholate, 0.1 % SDS, protease 
inhibitor and H2O) were added per 1x107 cells. 500 µL of the cell solution were transferred to a 
1.5 mL eppendorf tube and sonication for 3x 15 seconds with a 45 seconds pause on ice in 
between. The samples were centrifuged at 13,400 rpm for 3 minutes and the supernatant was 
transferred to a new tube. Hereof 50 µL were transferred to a new tube called “INPUT” and 
stored at -4°C. 
The samples were pre-cleaned with the Sepharose G beads (#17-6002-35 from Amersham 
Biosciences). 300 µL of the sonicated DNA were transferred to a new 1.5 mL eppendorf tube 
with 20 µL Sepharose G and incubated for 2 hours at 4°C on a rotating wheel at 14,000 rpm. 
The pre-cleaned solution was centrifuged 3 minutes at 2000 rpm and the supernatant was 
transferred to a new tube. To validate the sonication 10 µL were transferred to a new tube, 1 µL 
ProteinaseK was added and the solution was incubated for 20 minutes at 55°C. Afterwards, 4 µL 
loading buffer were added to the solution and run on a 1 % agarose gel.  
After the validation 50 µL of the pre-cleaned supernatant were tested with antibodies according 
to the kit ‘ChromaFlash™ One-Step ChIP Kit’s (#P-2025-48 from Epigentek™) protocol. 
For each cell line three antibodies were tested as shown in table 8. However, a new MBD2 
antibody was used because the old (MBD2a) were not produced anymore. The new antibody had 
the same properties as MBD2a. All antibodies are listed in appendix 9.4. 
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Table 8: Antibody treatments of ChIP samples – Samples were treated according to ‘ChromaFlash™ One-Step 
ChIP Kit’ with the kit’s solutions. Antibodies used for the samples were anti-MBD2, anti-MeCP2 and anti-IgG (NC).  
 Sample Positive control Negative control 
CH2 (ChIP buffer) 50 µL  50 µL 50 µL 
Chromatin 50 µL 50 µL 50 µL 
Antibody 2 µL - - 
H3 - 0.8 µL - 
GFP - - 0.8 µL 
 
The next day, 20 µL of Sepharose G were again added to the samples and incubated 2 hours at 
4°C on a rotating wheel with 14,000 rpm. The samples were centrifuged at 3000 rpm for 2 
minutes and the supernatant were discarded. The pellet was washed four times with 200 µL 
wash buffer and was then incubated twice for 3 minutes and centrifuged for 1 minute at 1000 
rpm and for 3 minutes at 2000 rpm and 3000 rpm the third and fourth time, respectively. The 
supernatant was transferred to a new tube, 39 µL CH3 (DNA release buffer) was added and was 
then incubated at 65°C O.N.. 
The following day 1 µL of proteinaseK (#39450-01-6 from Sigma) was added to each sample 
and the samples were then incubated at 55°C for 2 hours with 1400 rpm shake. The proteinaseK 
was inactivated by incubating the samples 1 minute at 95°C. The ChIP-DNA was stored at -
20°C. 
 
3.1.6 RNA interference 
RNAi decreases the function of a gene by degrading the associated mRNA. Here siRNA was 
used, to see if the MBPs have an effect to silencing the NDRG1-4.  
Different forms of siRNA exists, one of them being endoribonuclease-prepared siRNA 
(esiRNA). In this experiment MISISON® esiRNA was used to silence the MBPs esiRNA is long 
dsRNA and when it is in the cell it will be cleaved by dicer resulting in small fragment [Rees et 
al., 2005]. These fragment binds to the RISC complex as illustrated in figure 11 [Theis & 
Buchholz, 2010]. The cancer cell lines HCT116, DLD-1, SW480 and LoVo were used for this 
purpose. 
 
3.1.6.1 Transfection	  
50,000 cells were transferred to each well in a 24-well plate and was then incubated at 37°C for 
24 hours with McCoy medium containing FBS and P/S.  
Next day, the cells were transfected with Turbofect (#R0539 from Thermo Specific), pCMV-
EGFP plasmid (333,8 ng/µL), McCoy medium (without FBS and P/S) and either esiRNA-
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MeCP2 (#EHU030271-2006 from Sigma) or esiRNA-EGFP (#EHUEGFP from Sigma). The 
ratio of the components can bee seen in table 9. 
 
Table 9: Transfection – The transfection was done with different concentrations of Turbofect and esiRNA  
McCoy medium 300 µL 
Turbofect 3 or 6 µL 
esiRNA 3 µL, 7.5 or 15 µL 
  
pCMV-EGFP 6.3 µL 
 
The components were mixed in a LAF bench and incubated for 20 minutes. In the meantime 1 
mL new medium (with FBS and P/S) was transferred to each well. The transfection mix was 
then added to the wells drop-wise and the plate was incubated at 37 °C for the next 24 or 48 
hours. 
After the incubation period with the transfection mix, pictures were taken with a fluorescence 
microscope (Leicha DM IRB) to make sure the transfection was successful. After the pictures 
were taken the cells were harvested by either lysing the cells with trypsin or RIPA450++, 
depending on their following use. Before harvesting, the medium was removed, the cells were 
washed twice with PBS and lysed with 30 µL RIPA450++ was added to the wells followed by 30 
minutes incubation on ice, after which the samples were transferred to 1.5 mL eppendorf tubes 
and centrifuged 14,000g for 10 minutes at 4°C. The supernatant was transferred to new tubes 
and measured by Bradford protein assay. Afterwards the samples were run on a western blot as 
described above. All the samples were stored at -20°C. 
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4 Results	  
The following section contains the results of the experiment, which consisted of five parts: 
quantification of NDRG mRNA levels, methylation status, MBPs expression, ChIP and RNAi. 
The results are structured in the same order.  
 
4.1 Quantification of NDRG mRNA levels 
The mRNA levels of NDRG1-4 were detected in the four cancerous cell lines: HCT116, DLD-1, 
SW480 and LoVo. cDNA was made from RNA, which was isolated from the cell lines and 
quantified by qPCR with specific primers for the NDRGs.  
The qPCR data was compared to the mRNA expression levels of healthy human colon, 
normalized to RPLP0.The data collected from qPCR was normalized against RPLP0 according 
to Livak & Schmittgen (2001). The qPCR results are given as a threshold cycle (Ct) values, 
which indicate the cross point between the threshold line and the exponential phase of the 
fluorescence measurements [Life Tecnologies, n.d.]. All data and primers can be found in 
appendix 9.3. 
 
To compare the different mRNA levels of the NDRG family, a standard curve, which required a 
dilution series of cDNA was made. The cDNA was diluted 0x, 5x, 25x, 125x, 625x, 3125x and 
15,625x. The mRNA was measures in duplicates and the average values of the Ct were used to 
make the standard curve, which should give a slope between -3.3 and -3.6 (duplicates Ct value 
can be found in appendix 9.2.1.2.1). The line of the standard curve can be fitted, thus changing 
the efficiency, which should be between 80-100 %. As seen in figure 18, the standard curve for 
RPLP0 fulfills these requirements by having a slope of -3.362 and an efficiency of 98.4 %. 
 
 
Figure 18: Standard curve of RPLP0 – The standard curve is made from a dilution series (0x, 5x, 25x, 125x, 625x, 
3125x and 15,625x) of HCT116 cDNA. The duplicates Ct values can be found in appendix 9.2.1.2.1. 
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The amplification curve is important, because it demonstrates the accuracy of the duplicates, and 
hence the validation of the standard curve. The average of the duplicates is shown in figure 19 
(see appendix 9.2.1.2.1), have a close proximity to each other with an average of +2.32 Ct 
between them.  
 
Figure 19: Standard curve for RPLP0 – A dilution series from HCT116 cDNA consisting of 5x, 25x, 125x, 6125x, 
3125x and 15,625 diluted cDNA. Further, 125x diluted –RT cDNA and H2O (NTC) was run. The obtained threshold 
is 0.027. The dilution series are the first 7 curves (dark blue to purple) and the –RT and NTC is the light blue and 
orange, respectively. The duplicates Ct values can be found appendix 9.2.1.2.1. 
As indicated on the figure 19, both the no RT (33.81 Ct, orange) and the NTC (33.05 Ct, light-
blue) gave a Ct value, thus is showed that a product was amplified. The dissociation curve 
proved that this was due to contamination, since all the samples had the same melting 
temperature at 81.5°C (see appendix 9.2.1.2.2). However, the standard curve can be used due to 
the late detection in which it appeared (approximately +20 Ct from the undiluted samples). 
Previously, standard curves were made for NDRG1, 3 and 4 and therefore new standard curves 
were not made for these [Lorentzen, unpublished]. A standard curve for NDRG2 was made in 
the same way as done for RPLP0, as seen in figure 20. The amplification curve can be found in 
appendix 9.2.1.2.2.  
!
Amplification Plots 
120914 Standard kurve (HCT116, 0-15625) m RPLPO.mxp 
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Figure 20: Standard curve of NDRG2 – The standard curve are made from dilution series (0x, 5x, 25x, 125x and 
625x) of HCT116 cDNA. 
The standard curve for NDRG2 includes less dilution, because of imprecise Ct values between 
the duplicates (+2 Ct between the duplicates) and therefore the 3124x and 15,625x dilution was 
not included. The Ct values can be viewed in appendix 9.2.1.2.1..  
The threshold values for the NDRG family can be found in appendix 9.2.1.1. 
 
For the unknown samples, e.g. HCT116, DLD-1, SW480 and LoVo, the qPCR was performed in 
triplicates and with H2O as the NTC (all Ct values can be found in appendix (9.2.1.2.3). Here the 
threshold values for the NDRGs where used to obtain Ct values for the unknown samples. The 
mRNA expression for the NDRGs was compared to healthy colon tissue, which gave a relative 
value of the expression in the cancerous cell lines as illustrated in figure 20 (in appendix 9.2.1.2 
all the results are gathered and summarized in figure 42). The normalized NDRG mRNA 
expression values are relative number compared to the healthy colon tissue (given the number 
1). The relative number is indicated on top of the columns’ standard deviation. The levels of 
mRNA could not be detected (ND) in neither LoVo for NDRG4 nor in SW480 for NDRG1 as 
showed in figure 21. 
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Figure 21: NDRG mRNA expression – The NDRG qPCR data was standardized from the Ct values of a healthy 
colon according to Livak & Schmittgen (2001). Graphs were made in GraphPad prism 6. Standard deviations are 
indicated with the lines above the columns, and the numbers above the standard deviations are the normalizations 
values compared to healthy colon tissue (1.0). In NDRG1 and NDRG4 the mRNA could not be detected (ND) for 
respectively DLD-1, SW480 and LoVo. 
 
The normalized data shows an increased level of mRNA expression in DLD-1 for NDRG3 
compared to normal colon, though not significantly, while the remaining NDRGs show 
significantly decreased mRNA levels. 
The level of NDRG1 and NDRG2 is highest in SW480, while the mRNA levels are undetectable 
in the rest of the cell lines. NDRG3 is more expressed than NDRG1, NDRG2 and NDRG4. 
NDRG4 mRNA expression is highest in SW480 and significantly decreased in HCT116, DLD-1 
and SW480. 
 
4.2 Methylation status 
To demonstrate if the DNA were methylated in regard to the NDRG family, different methods 
were tested before a result was obtained. First, methyl-specific primers (MSP) for the NDRG 
family were tested for bisulfite treated cell lines, genomic DNA (negative control (NC)) and 
SAM+ SssI methylase treated genomic DNA (positive control (PC)), by conventional PCR (see 
appendix 9.5.1). The conventional PCR gave contradictory results, which led to optimization of 
the PCR reaction by a touchdown PCR. However, the touchdown PCR did not give any useful 
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results due to continued contamination (se appendix 9.5.1.1). Therefore, new primers were 
ordered, but these too gave contradictory results (data not shown). As a result, a new method 
was tested, where qPCR was used along with the MSP to compare the dissociation curves for 
methyl-specific primers and for non-methyl-specific primers. The result demonstrated that the 
dissociation temperatures were the same and therefore no conclusion in regard to methylation 
status could be obtained (see figure 51 and figure 52 in appendix 9.5.2). 
Next, methylated DNA immunoprecipitation (MeDIP) was performed to elucidate the 
methylation status, but the method did not give any results, not even for the positive control 
(anti-5-methylcytosine) and therefore the protocol was dismissed (see appendix 9.5.3). Finally, 
genomic sequencing of the bisulfite treated DNA from the cell lines were performed. 
 
The sequencing results were compared to the human genomic sequence of the NDRG family 
obtained from UCSC Genome informatics webpage. Further, the results were compared to the 
positive control and the negative control to validate the results (se figure 22 and 23 below).  
It was however not possible to determine the methylation status for NDRG3 due to inadequate 
bisulfite primers and NDRG2 was not tested since previous results was already available, 
demonstrating that NDRG2 was methylated [Lorentezen, unpublished]. The results for the 
individual NDRGs’ methylation status are presented below.  
 
4.2.1 NDRG1	  
Methylation of NDRG1 was obtained from bisulfite treated cell extracted DNA from HCT116, 
DLD-1, SW480 and PC as illustrated in figure 22. The sequencing results were compared to the 
original sequence, for which the NDRG1 specific primer set covered. The sequence can be found 
in appendix 9.2.2.1. 
The untreated NDRG1 sequence demonstrated 31 CpG site in the present CGI, maximally 
covered by the primer. However, the maximum amount of CpG site detected in the sequencing 
results was 2 CpG sites. The lower amount of CpG sites was properly due to primerbinding, 
which covered some of the CpG sites, and poor sequencing. 
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Figure 22: Methylation status for NDRG1 in various cell lines – Methylated CpG are illustrated with black circles 
and unmethylated CpG with white circles. The half black circles indicate that the sequence results detected showed 
both C and T at that position within the sequence. The quartered black dots indicate that a low amount of C was 
present for the given position. 
Due to the poor results for NDRG1 seen above, sequencing of NC was not performed. The 
sequencing results for HCT116, DLD-1, SW480 and PC have half-marked circles, which 
illustrates a high background interference. The background interference can be seen in the 
original sequence results (appendix 9.2.2.1). Even though the PC was not methylated, the rest of 
the results indicated that the tested DNA of the cell lines was not methylated for NDRG1.  
 
4.2.2 NDRG4	  
The methylation status of NDRG4 was obtained for bisulfite treated cell extracted DNA from 
HCT116, DLD-1, NC and PC. These results were likewise compared with the original sequence 
of NDRG4 (appendix 9.2.2.2). The untreated NDRG4 sequences demonstrated 17 CpG sites in 
the area covered by the bisulfite specific primer set. However, due to primer binding 12 CpG site 
remained, which is illustrated in figure 23. 
SW480 
HCT116 
PC 
DLD-­‐1 
1 2 5 4 3 6 7 8 9 10 11 12 
1 2 5 4 3 6 7 8 9 10 11 12 
1 2 5 4 3 6 7 8 9 10 11 12 
1 2 5 4 3 6 7 8 9 10 11 12 
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Figure 23: Methylation status for NDRG4 in various cell lines – Methylated CpG are illustrated with black circles 
and unmethylated CpG with white circles. The half black circles indicate that the sequence results showed both C and 
T at that given position within the sequence. The quartered black circles indicate that a low amount of C was present 
for the given position. 
The comparison between NC, PC, HCT116, DLD-1 and the untreated NDRG4 demonstrated 
respectively that 4/12, 5/12, 11/12 and 11/12 of the CpG were completely methylated.  
 
4.3 MBPs expression  
MBPs were detected at both mRNA and protein level to see if the MBPs were expressed in the 
cells. 
 
4.3.1 mRNA	  expression	  
The MBPs mRNA expression was determined by conventional PCR on cDNA, which was 
replicated two times (for full pictures see appendix 9.2.3) and RPLP0 was used as a semi-
quantification marker for mRNA amounts and as a positive control.  
The conventional PCR demonstrated that MeCP2, Kaiso and MBD2a mRNA are expressed in 
HCT116, SW480 and DLD-1. In the LoVo cell line MeCP2 and Kaiso are not expressed and 
MBD2a is less expressed compared to the other cell lines, as illustrated in figure 24. 
1 2 5 4 3 6 7 8 9 10 11 12 
1 2 5 4 3 6 7 8 9 10 11 12 
1 2 5 4 3 6 7 8 9 10 11 12 
1 2 5 4 3 6 7 8 9 10 11 12 
NC 
HCT116 
PC 
DLD-­‐1 
1 2 5 4 3 6 7 8 9 10 11 12 
1 2 5 4 3 6 7 8 9 10 11 12 
ND ND 
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Figure 24: MBPs expression on mRNA level – Conventional PCR of MeCP2, Kaiso and MBD2a cDNA from CRC 
cell line HCT116, DLD-1, SW480 and LoVo, gave 270 bp, 120 bp, 386 bp bands respectively. H2O was used as a 
negative control and RPLP0 as a positive control and a 1 kb marker (#1333 from Thermo Scientific) was used. 
As mentioned, the results were replicated and the results can be found appendix 9.2.3, which 
gave the same results.  
  
4.3.2 Protein	  level	  
The protein expression of MeCP2, Kaiso and MBD2a were determined by western blotting and 
the results demonstrated in figure 25. To show the total level of protein loaded β-actin was used. 
  
Figure 25: MBPs expression in protein level – Western blot was performed on protein isolated from HCT116, 
DLD-1, SW480 and LoVo, using the indicated specific primary antibodies. 
 
The result demonstrates, that the three proteins are expressed in HCT116, DLD-1, SW480 and 
LoVo. However, MeCP2 is expressed less in HCT116 and LoVo and Kaiso properly had en air 
bobble when β-actin was detected. These results were replicated, but without success (data not 
shown). 
 
4.4 ChIP 
To elucidate if the MBPs interacts with the chromatin ChIP was performed. ChIP was only run 
on HCT116 and SW480 cells with ChIP-NDRG4 primers (see appendix 9.2.4).  
H2 O LoV0 SW480 
DLD-­‐1 HCT116 
H2 O LoV0 SW480 
DLD-­‐1 HCT116 
H2 O LoV0 SW480 
DLD-­‐1 HCT116 
H2 O LoV0 SW480 
DLD-­‐1 HCT116 
MeCP2 Kaiso MBD2a RPLP0 270	  kDa 386	  kDa 120	  kDa 120	  kDa 
56	  kDa 80	  kDa 43	  kDa 
LoV0 SW480 
DLD-­‐1 HCT116 
LoVo	   SW480	  
 DLD-­‐1	  	   HCT116 
LoVo SW480 
DLD-­‐1 HCT116 
MeCP2 Kaiso MBD2a 
β-­‐actin β-­‐actin 43	  kDa 43	  kDa 43	  kDa 
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Before immunoprecipitation was performed, the sonication of the chromatin was validated by on 
a 1 % agarose gel after proteinaseK treatment. The ideal DNA fragment size are 200-1000 bp 
after sonication [Abcam, n.d.]. As illustrated in figure 26, most of the sonicated fragments were 
under 1000 bp. 
 
Figure 26: Chromatin sonication – the pre-cleaned chromatin was sonicated 3x 15 seconds, centrifuged and treated 
with proteinaseK.  
The results for ChIP were first demonstrated with conventional PCR, but due to water 
contamination and inconsistent results (data not shown), the ChIP results were run on qPCR. 
These results demonstrated that the contamination was due to another product in the samples, 
because of the different dissociation temperature as seen in figure 27 (NTC, green curve). 
Therefore, the data of the qPCR was used for further analysis. 
 
Figure 27: Dissociation curve for ChIP-samples – NTC is illustrated with green. All of the tested samples have 
dissociates at 86°C, where as NTC dissociates at 78.5 °C. NDRG4 primers.  
!
Dissociation Curve 
0515 chIP (SW480), Test med NDRG4-chIP primer (H3, IgG, MeCP2, INPUT(SW480), 
g.DNA og H2O).mxp 
Sonication 
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The amplification curve gives a quantification of amplified ChIP products, indication the amount 
of DNA-protein. As mentioned in the method section, anti-MeCP2, anti-MBD2, anti-H3 (PC) 
and non-immune-IgG (NC) were used, as illustrated on figure 28A and B. 
For HCT116 (figure 28A) the blue curve is anti-H3, the green is NC, the red anti-MeCP2 and the 
grey is anti-MBD2, while SW480 (figure 28B)’s anti-H3 is also blue curve, the red is NC, the 
grey is anti-MBD2 and the green is anti-MeCP2. For both the cell lines the same NTC control 
was used, illustrated with orange in the figures. 
  
Figure 28: Amplification curve of HCT116 and SW480 ChIP samples – A) HCT116: The amplification curve 
shows anti-H3 (blue), non-immune-IgG (green), anti-MeCP2 (red) and anti-MBD2 (grey). B) SW480: The 
amplification curve shows anti-H3 (blue), non-immune-IgG (red), anti-MeCP2 (green) and anti-MBD2 (grey). NTC is 
orange. 
To normalize the data, Ct values from anti-H3 were used, since no data were obtained from 
input. The Ct values obtain from the qPCR and the normalization of the data can be found in 
appendix 9.2.4 table 16. The Ct values for the tested chromatin-protein samples were therefore 
subtracted from anti-H3, to get an estimation of the amount of chromatin-protein interaction of 
the MeCP2 and MBD2 protein. The result is illustrated in figure 29.  
 
Figure 29: ChIP data normalized against anti-H3 – The cell line HCT116 and SW480 was used to demonstrate the 
interaction of the MBPs MeCP2, MBD2, where non-immune-IgG was used as a negative control and histone 3 (H3) 
was used to normalize the data, due to lack of input data. The graph illustrates a significant correlation between MBPs 
bound to SW480, where no significant correlation was found for the same MBPs in HCT116. The graphs were made 
in GraphPad prism 6, standard deviations is indicated with the lines above the columns, and the numbers above the 
standard deviations are the normalizations values compared H3 (1.0). 
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These results demonstrate that in the moment, when the SW480 cells were fixated, MeCP2 is 
4.41-fold increased, while MBD2 is 2.93-fold increased. Further, a student T-test demonstrated 
that the tested MBPs were significantly bound to the chromatin of the NDRG4 genes in SW480 
compared to bound non-immune-IgG chromatin-proteins. However, 0.54-fold increase of the 
MeCP2 and 0.08-fold increase of the MBD2 protein were bound in the HCT116 cells. These 
results were not significant, but in HCT116 the MBD2 interaction was 0.0025 from being 
significant. 
 
4.5 RNA interference 
As mentioned, RNAi was performed to elucidate if knockdown of MBPs was possible, with the 
purpose of investigating if MBPs play an important role in silencing of the NDRG. RNAi was 
performed on HCT116 for MeCP2 knockdown. The GFP protein was a control for the 
transfection efficiency and therefore pictures were taken with green fluorescence for all the wells 
per 24 hours they were transfected. 
 
4.5.1 Transfection	  efficiency	  
As mentioned, the transfected wells were photographed with a fluorescence camera. All the 
wells were transfected with the same amount of Turbofect and pCMV-EGFP plasmid. Further, 
the first row (1A-3A) was co-transfected with esiRNA-MeCP2, whereas the second row was co-
transfected with esiRNA-EGFP. The amount of esiRNA increased from row 1A to 3A, 200 ng, 
500 ng and 1000 ng respectively. The transfection results, as illustrated in figure 30, 
demonstrates a successful transfection after 24 and 48 hours.  
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Figure 30: 24 hours transfection of HCT116 co-transfected with plasmid pCMV-EGFP along with either 200 
ng, 500 ng or 1000 ng esiRNA– The transfection was performed with 300 µL serum-free medium, 3 µL Turbofect, 
6.3 µL pCMV-EGFP and between 3-15 µL esiRNA. 1A-3A was transfected with esiRNA-MeCP2 and 4A-6A with 
esiRNA-EGFP. The three columns (1A+4A, 2A+5A and 3A+6A) were transfected with 200 ng, 500 ng and 1000 ng 
esiRNA, respectively. 
The transfection results in figure 30 also demonstrate that the rows 1A-3A have an increased 
GFP transfection correlating with a higher concentration of esiRNA-MeCP2, while the co-
transfection with esiRNA-EGFP gives a lower amount of GFP fluorescence compared to row 
1A-3A. 
 
The samples were next tested on western blots. Here the primary antibodies anti-MeCP2 and 
anti-GFP (found in appendix 9.4) were used. The results obtained from the western blots were 
performed twice, both for the 24 and 48 hours transfection. The results obtained first are 
demonstrated in figure 31.  
The results obtained for anti-MeCP2, after 24 hours transfection, shows 56 kDa bands, as 
expected, where the intensity of the bands decreased with increasing concentration of esiRNA-
MeCP2. Since the esiRNA-EGFP treated proteins should not be affected by anti-MeCP2, no 
alterations are expected for lanes transfected with esiRNA-EGFP. The expected results were 
demonstrated as seen in figure 31 (MeCP2). Finally, to verify the loaded amount of protein β-
actin was detected. This showed that slightly less protein is loaded of the 1000 ng esiRNA-
MeCP2 treated protein. It is therefore likely that if an equal amount of protein were loaded that 
the 1000 ng esiRNA-MeCP2 band intensity would have increased. However, the results could 
not be repeated. 
  Page 52 of 94 
All anti-GFP demonstrates 43 kDa bands, though they were expected to show 27 kDa bands. 
However, anti-GFP has the least intense band for the 200 ng concentration, the highest intensity 
for 500 ng and a slightly decreased intense band for 1000 ng compared to the 500 ng band. Anti-
β-actin revealed less loaded protein for the 200 ng esiRNA-EGFP treated protein. Thus, if an 
equal amount of protein were loaded, the results would have shown decreasing band intensity in 
correlation with the higher concentration of esiRNA-EGFP. 
 
Figure 31: Western blots of esiRNA transfected HCT116 cells after 24 hours treatment with either 200 ng, 500 
ng or 1000 ng esiRNA – Extracted protein of esiRNA transfected cells were run on SDS-PAGE and subsequently 
transferred to western blots and tested with anti-MeCP2, anti-GFP and anti-β-actin. 
As mentioned, the blotting was replicated to validate the results. However, the replication gave 
no results (data not shown).  
The conclusion for the 24 hours transfected cells is that a correlation between the decreasing 
intensity of the bands and increased concentration of esiRNA can be observed.  
However, the MBP was not knocked down and therefore, transfections were made with the same 
concentrations of esiRNA, but were incubated for 48 hours instead. The 48 hours transfection 
efficiency is illustrated in figure 32.  
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Figure 32: 48 hours transfection of HCT116 co-transfected with plasmid pCMV-EGFP along with respectively 
200 ng, 500 ng or 1000 ng esiRNA– The transfection was performed with 300 µL serum-free medium, 3 µL 
Turbofect, 6.3 µL pCMV-EGFP and between 3-15 µL esiRNA. 1A-3A were transfected with esiRNA-MeCP2 and 
4A-6A with esiRNA-EGFP. The three columns (1A+4A, 2A+5A and 3A+6A) were transfected with 200 ng, 500 ng 
and 1000 ng esiRNA respectively. 
The 48 hours transfected protein samples showed inconsistent results in western blots, when 
trying to obtain replications. Both anti-MeCP2 and anti-GFP showed bands with the wrong size 
and β-actin could not be detected, as illustrated in the figure 33. First MeCP2 was tested 
followed by GFP and β-actin. Between each antibody the blot was stripped and blocked. 
 
Figure 33: Western blot of esiRNA treated HCT116 cells after 48 hours treatment with respectively 200 ng, 500 
ng or 1000 ng esiRNA– Extracted protein of esiRNA transfected cells were run on SDS-PAGE and subsequently 
transferred to western blots and tested with anti-MeCP2, anti-GFP and anti-β-actin. 
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  esiRNA-­‐MeCP2 
27	  kDa Data	  not	  obtained 
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The blots did not show any significant alterations in regards to the amount of esiRNA used and 
therefore another transfection plate was set up with a higher concentration of esiRNA on 1300 
ng or 1500 ng to knockdown MeCP2. As before, pictures were taken to show the transfection 
efficiency, to look at the GFP fluorescence as seen in figure 34. 
 
Figure 34: 48 hours transfection of HCT116 co-transfected with GFP along with 1300 ng or 1500 ng esiRNA – 
The transfection was performed with 100 µL serum-free medium, 6 µL Turbofect, 6.3 µL pCMV-EGFP and either 6.5 
µL (1300 ng) or 7.5 µL (1500 ng) esiRNA. 1A and 3A were transfected with esiRNA-MeCP2 and 2A and 4A with 
esiRNA-EGFP. 1A and 3A were transfected with 1300 ng and 2A and 4 A with 1500 ng esiRNA. For each well, a 
picture was taken showing only GFP and a light microscopy picture of the cells was added as a reference.   
 
The pictures indicate that the transfection was not as efficient as the previous. Out of the total 
amount of cell, only a very small fraction of the cells showed successful transfection with the 
GFP plasmid. As shown in figure 34, each well had a considerably high amount of cells so the 
individual cell could not be seen. It was not possible to redo the transfections and therefore the 
samples from the 1300 ng and 1500 ng transfections were used to make western blot as before. 
As controls untransfected cell was used. The blots were not tested with the same antibodies, but 
a new anti-GFP (#sc-8334 from Santa Cruz). Due to inconsistent results and loss of proteins 
from the blots, four blots were made.  
The first blot was incubated with anti-MeCP2 and anti-GFP giving 70 kDa bands for both 
antibodies, though respectively 56 kDa and 27 kDa band were expected, as illustrated in figure 
35. Next, anti-β-actin was used, but no results were obtained after stripping, blocking and 
incubating with a new antibody. This was due to loss of protein, which was demonstrated by 
ponceau red staining (data not shown). 
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Figure 35: Western blot of esiRNA treated HCT116 cells extract after 48 hours treatment with 1300 ng or 1500 
ng esiRNA – Extracted proteins of esiRNA transfected cells were run on a SDS-PAGE and subsequently transferred 
on a western blot and tested with anti-MeCP2, anti-GFP and anti-β-actin. This gave 70 kDa bands for anti-MeCP2 and 
for anti-GFP. The blot was rejected, due to disappearance of protein after multiple runs with anti-β-actin that did not 
give any results. Anti-GFP was expected to give 27 kDa, but gave 70 kDa band. The controls were untransfected cells, 
e.g. not transfected with either esiRNA or pCMV-EGFP, and therefore they were not expected to show bands when 
treated with anti-GFP. 
A second blot was made, but with the addition of purified GFP protein to test the new anti-GFP 
antibody. Incubation with anti-GFP showed two bands, a strong 27 kDa, which was also 
detected in the lanes not containing any proteins and a 70 kDa band as illustrated in figure 36. 
Again, results for the other antibodies could not be obtained due to protein loss. Therefore the 
blot was repeated.  
 
Figure 36: Western blot of esiRNA treated HCT116 cells after 48 hours treatment with 1300 ng or 1500 ng 
esiRNA – Extracted proteins of esiRNA transfected cells were run on a SDS-PAGE and subsequently transferred on a 
western blot and tested with anti-GFP. Purified GFP protein was added to verify GFP band size. The right 27 kDa 
band appears along with a 70 kDa (unknown), but after stripping and incubation with the second antibody, the 
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proteins had disappeared again. The controls are untreated cells, e.g. not transfected with either esiRNA or pCMV-
EGFP, therefore they are not expected to give bands when treated with anti-GFP. 
The repeated third blot showed in figure 37 was first incubated with anti-β-actin, which gave the 
expected bands at 43 kDa in all samples except for the purified GFP-protein. Next, anti-GFP 
approximately gave the expected 27 kDa bands for both the samples and the purified GFP-
protein along with unspecific bands on 100 and 55 kDa, for the samples, and 70 kDa for the 
purified GFP-protein.  
 
Figure 37: Western blot of esiRNA treated HCT116 cells after 48 hours treatment with 1300 ng or 1500 ng 
esiRNA - Extracted proteins of esiRNA transfected cells were run on a SDS-PAGE and subsequently transferred on a 
western blot and tested with anti-GFP and anti-β-actin. The blot was first incubated with anti-β-actin, follow by anti-
GFP. Anti-GFP gave the expected 27 kDa bands, along with unspecific bands at 10 and 55 kDa, while the purified 
protein gave 27 and 70 kDa bands. Anti-β-actin only gave the expected 43 kDa band. The controls are untreated cells, 
e.g. not transfected with either esiRNA or pCMV-EGFP, therefore they are not expected to give bands when treated 
with anti-GFP The controls are untransfected cells, e.g. not transfected with either esiRNA or pCMV-EGFP, therefore 
they are not expected to give bands when treated with anti-GFP. 
To verify the results for anti-GFP, a fourth blot was made. The fourth blot, which had 10x 
diluted GFP protein, was tested with anti-MeCP2 first due to a lack of anti-MeCP2 results. 
Following, anti-GFP and anti-β-actin was tested as illustrated in figure 38. This yielded weak 
bands of 10, 35 and 70 kDa and a stronger one of 27 for anti-MeCP2. For anti-GFP the purified 
GFP protein bands of 27 and 70 kDa were shown, while anti-β-actin showed 43 kDa bands for 
all samples, except for the GFP protein.  
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Figure 38: Western blot of esiRNA treated HCT116 cells after 48 hours with 1300 ng or 1500 ng esiRNA – Cell 
extract from esiRNA transfected cells were run on western blot and tested with anti-MeCP2, anti-GFP and anti-β-
actin. A 10x dilution of the purified GFP was added on the blot to diminish the signal of anti-GFP. Anti-MeCP2 gave 
10 and 35 kDa bands, anti-GFP gave 27 and 70 kDa and anti-β-actin gave 43 kDa bands.  
Further a western blot, kindly provided by Joyce Heuninck, was likewise co-transfected with 
pCMV-EGFP and tested with anti-GFP. The blot from Heuninck, in figure 39, showed a strong 
27 kDa band, but also 43 kDa and 55 kDa bands. The 43 and 55 kDa bands were due to 
insufficient stripping of the blot with previously used antibodies. 
 
Figure 39: Anti-GFP Test - The blot (kindly provided by Joyce Heuninck) was also co-transfected with pCMV-
EGFP, though on HEK293 cells, were tested with anti-GFP, which resulted in a 27 kDa band. The controls are 
untransfected cells, e.g. not transfected with either esiRNA or pCMV-EGFP, therefore they are not expected to give 
bands when treated with anti-GFP. 
This blot proved that the anti-GFP antibody works. The results obtained from RNAi after 
treatment with 1300 ng and 1500 ng esiRNA, indicated a correlation between increased 
concentration of esiRNA-MeCP2 and knockdown of the MeCP2 protein (figure 35).
GFP 
27	  kDa 
55	  kDa 
Joyce	  blot,	  HEK923	  cell.	  These	  cells	  were	  also	  transfected	  with	  pCMV-­‐GFP 
Anti-­‐GFP	  test 
  Page 58 of 94 
5 Discussion	  
Epigenetic regulation has been elucidated as one of the mechanisms involved in tumorigenesis, 
in which the NDRG family has been implicated. Both NDRG1 and NDRG2 have been 
thoroughly studied and shown to have oncogenic and tumor suppressive effects in CRC and both 
are demonstrated to function as TSGs. NDRG3 and NDRG4s functions are not clear in 
tumorigenesis, however the few studies that have been performed shows that NDRG3 is 
oncogenic in prostate cancer and that NDRG4 is a TSG in CRC.  
This thesis provides further elucidation of how the NDRG genes are expressed and regulated in 
CRC cell lines, and how MBPs bind to the epigenetically altered DNA.  
 
5.1 NDRG mRNA expression 
The mRNA expression levels of the NDRG family were detected by using qPCR to demonstrate 
if the mRNA were altered compared to healthy colon tissue.  
 
5.1.1 NDRG1	  
The mRNA levels of NDRG1 were significantly down-regulated in HCT116 and LoVo and were 
undetectable in DLD-1 and SW480 compared to healthy colon (figure 21). These results 
correspond with the findings made by Guan and colleagues (2000), in whose study HCT116, 
DLD-1, SW480, and LoVo were also used. However, in their study the untreated CRC cell lines 
were compared with 5´-aza-2’-deoxycytidine treated cells. This demonstrated a higher NDRG1 
mRNA level in treated CRC cells, therefore the NDRG1 gene must have been epigenetically 
methylated. Many studies conclude that NDRG1 has a low expression in CRC [Fang et al., 
2014; Shah et al., 2005; Koshiji et al., 2007]. These findings correlate with the thesis’ results. 
The overall conclusion of NDRG1´s effect on cancer is contradictory, in terms of the expression 
level is high or low compared to healthy tissue, and thus it has been postulated that NDRG1 
affects tumor- and metastasis-suppressors [Fang et al., 2014]. As mentioned, the contradictory 
results could be due to different stages of CRC samples were used to elucidate the role of 
NDRG1, since different stages of CRC have different level of NDRG1 [Shah et al., 2005]. 
 
5.1.2 NDRG2	  
In all the cell lines, the level of NDRG2 mRNA was significantly down-regulated compared to 
healthy colon. This corresponds with fact that the level of NDRG2 has been reported to be 
down-regulated in many types of cancer [Lorentzen et al., 2007; Lorentzen et al., 2011]. The 
down-regulation correlates with the results demonstrated by Feng and colleagues (2011). In their 
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study SW480 and LoVo were used to compare the cells to 5´-aza-2’-deoxycytidine treated cells. 
This demonstrated a higher NDRG2 mRNA level in treated CRC cells, and therefore the 
NDRG2 gene must have been epigenetically methylated.  
 
5.1.3 NDRG3	  
For NDRG3, the levels of mRNA were down-regulated significantly in HCT116 and SW480, 
while LoVo demonstrated a tendency of down-regulation. However, according to the student T-
test, LoVo was not significant down-regulated. In DLD-1, the normalization exposed an up-
regulation for NDRG3, though not significantly. The mRNA levels of NDRG3 were in general 
higher than observed for the rest of the NDRG family when compared to normal tissue. As 
mentioned, few studies have been performed to elucidate the role of NDRG3 in cancer [Wang et 
al., 2009]. More work is therefore needed to verify the resuls before any conclusion can be made 
in regard of NDRG3 and its role in CRC. 
 
5.1.4 NDRG4	  
The levels of NDRG4 mRNA demonstrated a significant down-regulation for HCT116, DLD-1 
and LoVo, while the level of mRNA was not detectable in SW480.  
As mentioned, few studied have been performed to elucidate the role of NDRG4 in cancer. 
Melotte and colleagues (2009) studied the level of mRNA in HCT116 by treating CRC cell lines 
with HDACi, which demonstrated that the level was down-regulated compared to non-treated 
CRC cell lines [Melotte et al., 2009]. These results correspond with the results obtained within 
this thesis. 
In general, the level of NDRG4 mRNA in LoVo was lower than in the rest of the CRC cell lines. 
This could be due to the fact that LoVo is derived from metastatic cancer, while the others are 
from primary CRC [Guan et al., 2000]. However, further studies are required to conclude if this 
is the case. 
 
To elucidate if the altered mRNA level is due to epigenetic alterations the methylation status 
were investigated of the NDRGs. 
 
5.2 Methylation status 
As mentioned, several methods were attempted before results could be obtained regarding the 
methylation status of NDRG1, NDRG3 and NDRG4. Work with NDRG2 was not performed, due 
to results already being available.  
 
  Page 60 of 94 
 
MSP primers 
Studies have previously been demonstrated that the MSP works on cancerous cells, e.g. HCT116 
and SW480, and that the promoter of NDRG2 is methylated [Lorentzen, unpublished; Piepoli et 
al., 2009]. Therefore the protocol for MSP was optimized. The annealing temperature was first 
changed, but due to inconsistent results, touchdown PCR was performed without success, in an 
effort to optimize the conventional PCR protocol. The optimization was unsuccessful, probably 
due to a wrongly programmed hot-start of the maxima hot-start enzyme, which was set to 95°C 
for 15 minutes instead of 4 minutes. Thus, it is likely that most of the polymerase containing hot-
start enzyme, had disappeared. Nevertheless, the PCR reactions gave visible bands and therefore 
the enzyme must have worked to some degree, which might explain the contradictory results, 
both for MSP and touchdown PCR (appendix 9.5.1 and 9.5.1.1, respectively). Unfortunately this 
mistake was recognized to late in the process and in an attempt to get useful results, qPCR was 
performed. 
 
Dissociation curve 
Methylated DNA contains a higher amount of CGs than ATs and because of the higher amount 
of hydrogen bonds in CG, it was expected that methylated DNA would have a higher 
dissociation temperature. Therefore of the methylation status was elucidated with qPCR. 
The qPCR did not give any results that indicated an alteration in dissociation temperature when 
methyl-specific and unmethyl-specific primers were used. However, the bisulfite specific primer 
for NDRG3 did not give any measurable dissociation curve. Therefore it could be concluded that 
the bisulfite specific primers did not work, and therefore new bisulfite primers were required. 
However due to limited time, these were not purchased and all work with NDRG3 was halted.  
Despite the lack of results, NDRG3 has been reported to be primarily expressed in the testes and 
to function in spermatogenesis and acts as an oncogene in prostate cancer [Wang et al., 2009; 
Zhao et al., 2001]. In this study it is demonstrated that NDRG3 is up-regulated in the CRC cell 
line DLD-1, however not significantly. This data were obtained from technical replicates, and 
therefore more studies with biological replicates in CRC cell lines are necessary to elucidate 
NDRG3’s role as an eventual oncogene.  
 
 
Sequencing 
Before sending the PCR products to sequencing, the bisulfite specific primers were tested with 
conventional PCR and run on a 1 % agarose gel. These results demonstrated bands for all of the 
tested samples except for the negative control. Therefore, the PCR products for NDRG1 and 
NDRG4 were purified and sequenced. The sequencing results for NDRG1 showed that many of 
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the CpG sites had vanished compared to the original sequence (appendix 9.2.2.1) and few CpGs 
were methylated in PC, HCT116 and DLD-1. This indicated that NDRG1 was not methylated in 
the CRC cell lines. However, the sequencing demonstrated a long repetition of the same 
nucleotides, which complicates the sequencing for the polymerase, due to binding difficulty. All 
this together indicates that the sequencing was of poor quality. Due to the lack of methylation in 
the PC, it should to be repeated to confirm that NDRG1 is unmethylated. However, the 
methylation status for NDRG1 correlates with a study performed by Lind and colleagues (2006). 
In the study 20 CRC cell lines were bisulfite treated and examined by using MSP, which 
demonstrated that the promoter region was not methylated in any of the cell lines, e.g. HCT116, 
SW480 and LoVo.  
 
The sequenced area with bisulfite specific primers for NDRG4 showed that close to 100 % 
(11/12) of the CpG was methylated compared to the original sequence (appendix 9.2.2.2.). It can 
therefore be concluded that NDRG4 is methylated for the tested area. 
Melotte and colleagues (2009) investigated the methylation status of NDRG4. The study was 
performed on HCT116 and SW480 cells, which was also investigated with MSP and genomic 
sequencing on bisulfite treated cells. The result demonstrated that HCT116 was methylated, 
corresponding with the result demonstrated in this thesis.  
 
As mentioned, a lot of work has previously been done with NDRG2. In these studies it has been 
demonstrated that the NDRG2 promoter is methylated in various CRC cell lines, e.g. HCT116, 
SW480 and LoVo [Melotte et al., 2010; Piepoli et al., 2009; Feng et al., 2011]. 
 
5.3 MBPs expression 
In this study the MBPs expression was investigated on mRNA level and on protein level by 
conventional PCR and western blotting, respectively. 
The study investigating mRNA level on the CRC cell lines and demonstrated that the MBPs 
MeCP2, Kaiso and MBD2(a) were expressed in for all the cell lines. However, the expression of 
MBPs mRNA in LoVo was lower compared to the level for the other cell lines. The same result 
was obtained, when the PCR reaction was repeated (see figure 45 in appendix 9.2.3). However, 
mRNA level does not confirm that their encoded protein is present. Therefore western blotting 
was performed to elucidate if the MBPs could be detected on protein level.  
The western blots demonstrated that all of the proteins were present in HCT116, DLD-1, SW480 
and LoVo. In an effort to validate the results, the blots were repeated, but without success. Since 
results were obtained with the same antibodies later (RNAi), the different results could not be 
due to unspecific bindings or insufficient dilutions. Further, the same amounts of proteins were 
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loaded and the same detection kit was used. However, later work with western blot (RNAi) 
demonstrated loss of protein on the western blot, which was not examined here. It is therefore 
possible that the protein had vanished. Further, the later western blot had repeated failure to 
detect proteins, but after the detection kit was changed to a more sensitive kit, results were 
obtained. Therefore the MBPs western blot should have been tested with ponceau red and if the 
proteins were lost they should have been redone. Further the more sensitive detection kit should 
have been used.  
However, the presence of the MBPs has been demonstrated in CRC cell lines by others: Lopes 
and colleagues (2008), Berg & Bird (2005) and Lorentzen, unpublished. Therefore the first 
results obtained for MBPs were accepted. 
Since the MBPs were detected on both mRNA and protein level, a ChIP study was performed to 
elucidate if there were an interaction between the MBPs and the chromatin in the NDRG4 gene, 
since it was the only one proven to be methylated. 
 
5.4 ChIP 
The ChIP results demonstrated that there is an interaction between the NDRG4 chromatin and 
the MBPs MeCP2 and MBD2. These interactions were elucidated with antibodies for MeCP2, 
MBD2, a PC (anti-H3), a NC (non-immune-IgG) and a NTC (H2O). 
The qPCR amplification figure for HCT116 (figure 28A) shows that chromatin connected with 
H3 was present in a higher amount, since it was detected first with anti-H3. This result was 
expected, because H3 is a part of all chromatin assembling. Non-immune-IgG was detected as 
second highest level. As mentioned, the ChIP data was first demonstrated by conventional PCR, 
which also showed amplification of non-immune-IgG. The amplification of the NC could be due 
to background noise, unspecific bindings or insufficient cleaning of the ChIP product. Due to 
lack of input data to normalize the non-immune-IgG data, the relative level could not be 
demonstrated and therefore background noise levels cannot be excluded. However, a pre-
cleaning was performed to prevent unspecific binding products. However, in further studies the 
step could probably be optimized.  
The qPCR demonstrated amplification of the NTC, but a different dissociation temperature and 
therefore it was not a contamination. However, amplification was also seen for the NC, but these 
samples had the same dissociation temperature (se figure 44 in appendix 9.2.5). This means that 
the results obtained for the NC were not due to contamination. As mentioned, input data is used 
to normalize ChIP data, which would give a percentage of the presence of MBPs compared to all 
chromatin detected in the ChIP assay. The normalization with the input data could have 
elucidated whether the NC data were due to binding of unspecific background chromatin.  
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Instead data from anti-H3 was used to normalize the data, because H3 should be presence in all 
chromatin and therefore the PC data was the closest to input data. For HCT116 this gave a 
percentage of 0.54 % MeCP2 and 0.08 % MBD2 protein, which was bound to the chromatin 
compared to the PC. The same normalization method was used for SW480 and gave a 
percentage of 4.41 % for MeCP2 protein and 2.93 % of MBD2. For statistical analysis the 
samples were compared to the NC, as a measurement for unspecific binding. For the HCT116 
data there were no significance difference compared to NC, but MBD2 was very close. SW480 
demonstrated significance for both the MBPs, though indicating that MeCP2 and MBD2 bind to 
the NDRG4 promoter in the SW480 cell line.  
As mentioned, Melotte and colleagues (2009) investigated the methylation status of NDRG4 in 
HCT116, but also in SW480. In SW480 the showed that only few CpG sites were methylated, 
which led them to the conclusion that the promoter region was not methylated. It could therefore 
be interesting to see if the same results could be obtained, since the MBPs in this thesis were 
shown to bind significantly on NDRG4 chromatin in SW480. However, ChIP was only 
performed once in this thesis and therefore repetitions of the study are necessary to confirm the 
interaction between the MBPs and the chromatin. 
 
In further studies a different NC could be used, since the non-immune-IgG antibody binds 
unspecific. Therefore anti-GFP could be used, since this should not bind to anything. Further, 
qPCR was only performed once on the ChIP samples. Thus, no conclusion can be made of these 
results. However, the results indicate an interaction of the MBPs on NDRG4 chromatin. 
 
5.5 RNA interference 
In this study, the promoter of NDRG4 was methylated in the cell lines HCT116, DLD-1, SW480 
and LoVo. Previous studies have demonstrated that the promoter of NDRG2 is also methylated 
in HCT116 and SW480 [Lorentzen, unpublished]. Further the MBPs MBD2, MeCP2 and Kaiso 
have been detected at mRNA level and at protein level, but the interaction of the MBPs with 
NDRG4 chromatin could not be confirmed due to lack of repetition. However, the results 
indicate that MeCP2 and MBD2 interact with the NDRG4 chromatin. Lastly, RNAi knockdown 
study of MeCP2 was performed to elucidate their role in epigenetic silencing in HCT116.  
 
24 hours transfection 
esiRNA was transfected in different concentrations (200 ng, 500 ng and 1000 ng) in HCT116 
cells and evaluated after 24 hours by isolation proteins from the cell extract of the treated cells. 
Subsequently the proteins were transferred to a blot, which were treated with antibodies. Before 
the blot was used ponceau red wad used to detected if the protein amount was equal (data now 
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shown). The anti-MeCP2 showed bands for all of the samples (see figure 31, anti-MeCP2). Cells 
transfected with 1000 ng esiRNA-MeCP2 showed a slightly weaker band, while the esiRNA-
GFP treated samples showed the same level of expression. Next, the blot was incubated with 
anti-GFP where the sample treated with the smallest concentration showed the weakest band, 
thus indicating less GFP protein was present, when less siRNA was added (figure 31, anti-GFP). 
This was unexpected since esiRNA-EGFP should knockdown the GFP proteins. Finally, when 
results were obtained from anti-β-actin (figure 31, anti-β-actin) and compared to the anti-GFP 
results it showed that less protein was loaded for the 200 ng concentration. Therefore, if an equal 
amount of protein were loaded, the band intensity would have been bigger. Had the anti-GFP 
band been bigger, the results would have followed the same tendency, as increased for the 
MeCP2 knockdown.  
Combined this indicates that the higher the concentration of the esiRNA-MeCP2 the better the 
knockdown of MeCP2 mRNA works. These results could not be obtained again when the 
experiment was repeated and the blots lack controls, thus no conclusion can be made. Further, 
the used concentrations were unable to knockdown the MeCP2 and GFP. Therefore the HCT116 
cells were treated with esiRNA for 48 hours to see if the MBPs would be knocked down. 
 
48 hours transfection 
The results after 48 hours transfection were contradictory to the results after 24 hours 
transfection, due to wrongly detected bands sizes and lack of correlation between esiRNA 
concentrations and band intensity. As for the blots before, anti-MeCP2 was the first tested 
antibody followed by anti-GFP and anti-β-actin, except for blots demonstrated in figure 36 and 
37.  
The work with western blots demonstrated many obstacles, both with detection of proteins, but 
also with insufficient stripping of the blot as seen in figure 33. Here the stripping was 
insufficient between anti-MeCP2 and anti-GFP. Further, all the detected bands were the wrong 
size and data could not be obtained for anti-β-actin (figure 33). However, the 24 hours treatment 
showed the right correlation between the esiRNA concentration and the intensity of the bands. 
Therefore, the 48 hours samples were dismissed and a new transfection was made with higher 
esiRNA concentrations. 
 
The new transfection was performed with higher esiRNA concentrations and was likewise 
transferred to a blot. Before the blot was used ponceau red wad used to detected if the protein 
amount was equal (data now shown). As mentioned the new blots showed contradictory results. 
On the first blot, anti-MeCP2 demonstrated a correlation with the concentration of esiRNA-
MeP2 (figure 35) since samples treated with both 1300 ng and 1500 ng esiRNA-MeCP2 had an 
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almost undetectable amount of the MeCP2 protein compared to the esiRNA-GFP treated 
samples and control 1. However, the detected bands for anti-GFP were 70 kDa, which was 
higher than expected. Therefore a purified GFP protein was added as a control on a new blot. 
The purified GFP control showed strong bands when incubated with anti-GFP and gave both the 
expected size (27 kDa) and the previously seen band size of 70 kDa (figure 36, 37 and 38). 
To decrease the band intensity for the purified protein it was diluted 10x (figure 38). However, 
when anti-GFP was used on the fourth blot only the purified protein demonstrated a signal at 70 
and 27 kDa. 
 
Anti-GFP and transfection efficiency  
Because of contradictory results in both the MBPs expression study and for the knockdown 
study, it might reflect that the antibody binds unspecific. However, anti-GFP recognizes the right 
27 kDa band in some of the blots. It is therefore possible that the antibody has a different 
recognition site, since the 70 kDa was seen repeatedly. It should be considered however, that the 
poor results for the higher concentrations of esiRNA could correlate with the poorer transfection 
efficiency (figure 34) since Lopes and colleagues’ (2008) previous successful demonstrated the 
effect of Kaiso with siRNA knockdown. 
The study of Lopes and colleagues (2008) was also performed in HCT116, however their study 
differs in the choice of transfection agent where Lipofectamine (Invitrogen) was used. Oba & 
Tanaka (2012) elucidated the effect of three transfection agents (Pro-DeliverIN, Xfect and 
Turbofect), which showed that Turbofect had the highest protein transfection efficiency of the 
three, thus a competent transfection agent. Further, the fluorescence pictures (figure 30 and 32) 
proved that the Turbofect worked.  
 
Consequently, the results demonstrate that the NDRG4 level in CRC is down-regulated due to 
methylation of the promoter region. Also, the MPBs are expressed both at mRNA and protein 
level and ChIP assay illustrated that MBPs interacts with NDRG4 chromatin. However, the 
RNAi study did not provide any usable results, therefore it was not possible to investigate the 
effects of MBPs in regard to its epigenetic effect on the NDRG.   
 
  Page 66 of 94 
6 Conclusion	   	  
From the study it can be concluded that the mRNA expression of the NDRG family is down-
regulated in the tested CRC cell lines compared to healthy colon tissue. However, NDRG3 is 
less down-regulated than NDRG1, NDRG2 and NDRG4. Further, NDRG3 might be up-
regulated in CRC, but more replicates are needed to conclude anything. It can also be 
concluded that NDRG4 is methylated for the tested promoter region, while NDRG1 is most 
likely unmethylated.  
For the MBPs it can be confirmed that they are present on both mRNA and protein level in 
the CRC cell lines. The use of ChIP demonstrated that MBD2 and MeCP2 interacted with the 
NDRG4 methylated promoter region in the CRC cell line SW480. The use of RNAi with 
different concentrations to knockdown MeCP2 gave promising results. The higher 
concentrations of esiRNA-MeCP2 gave lower signals upon detection on a western blot with 
an anti-MeCP2 antibody, which proved that there indeed is a correlation between the used 
concentrations for RNAi and the tested MBPs. 
7 Perspective	  
To extend the results in this study, further studies are needed to elucidate the effect of NDRGs 
in CRC. First, the methylation status of NDRG1 should be confirmed, and the status of 
NDRG3 should be determined to see if the promoter is affected by epigenetic alterations. This 
could be done by constructing new primers or by selecting a new CGI site. Next, ChIP should 
be performed to determine if MBPs interact with the NDRG3 promoter, as is the case for 
NDRG4. With the NDRG4 a tendency could be demonstrated for the knockdown of MeCP2, 
however this needs to be repeated to confirm that the esiRNA knocked down the MBPs. If the 
effect of RNAi could be demonstrated, further work could be made to elucidate the MBPs 
role in the silencing of NDRG4 and other NDRGs. This could be done by treating the cell 
lines with a DNA demethylation agent e.g. 5’-aza-2’-deoxycytidine or a histone deacetylating 
agent (HDACi) and subsequently analysing the effect of the treatments in regards to the 
expression of NDRG4. qPCR could then be performed to see if the mRNA levels would be 
altered. If such a study showed an increase in mRNA expression of the NDRGs, it would 
confirm whether the MBPs truly play a role in the silencing of the genes. 
In general, a more adequate knowledge of epigenetics is required in regard to epigenetic 
silencing mechanisms. Different enzymes affect alterations in the body as seen for the HATs, 
HDACs and HMTs. The enzymes have been implicated in numerous pathways and therefore 
  Page 67 of 94 
in numerous mechanisms e.g. for embryonic development [Lin & Dent, 2006]. These 
enzymes affect cellular functions throughout life, therefore the regulation and maintenance of 
these enzymes important and therefore they should be studied more thoroughly in role in 
cancer. It is likely that they play a crucial role in carcinogenesis and therefore the interaction 
of the different epigenetic mechanisms should be studied together to elucidate their relational 
functions. However, most of the epigenetic mechanisms are dynamic, thus complicating the 
determination of their functions in cancer.  
The NDRG family members have distinct functions, and therefore their role in cancer has 
been difficult to demonstrate. However, new studies indicate that the contradictory results 
regarding the effects of the NDRG genes in cancer e.g. NDRG2 could be due to isoforms 
created by alternative splicing [Mitchelmore, unpublished]. This can lead to altered structure 
and function of the genes, if the splicing affects the N- and C-terminal regions, since they are 
responsible for the individual roles of each member [Zhou et al., 2001]. Therefore, more 
research is needed both to elucidate alternative splicing sites of the genes, but also to 
elucidate cross-talk between the NDRG genes and epigenetic mechanisms.  
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9 Appendix	  
9.1 Markers 
     PCR      Western blot 
     
 
9.2 Raw data 
9.2.1 NDRG	  mRNA	  expression,	  qPCR	  results	  
The section contains the threshold values for NDRG1-4 [Lorentzen, unpublished] along with 
raw data from all the qPCR. 
 
9.2.1.1 Threshold	  values	  for	  NDRG1-­‐4	  
The threshold values for NDRG2 are obtained by qPCR. 
Table 10: Threshold value for NDRG1-4 – The threshold of NDRG1, 3 and 4 were obtained from previous students, 
while the threshold of NDRG2 was obtained by qPCR 
 Threshold values 
NDRG1 0.009 
NDRG2 0.028 
NDRG3 0.035 
NDRG4 0.040 
 
9.2.1.2 Quantification	  of	  mRNA	  
The quantification of mRNA was obtained by qPCR, which was performed on healthy colon 
tissue, HCT116, DLD-1, SW480 and LoVo for NDRG1-4. The data (Ct values) was normalized 
by calculating Δct followed by ΔΔct. The ΔΔct values were normalized with the formula 2^ΔΔct 
  Page 79 of 94 
9.2.1.2.1 Standard	  curves’	  Ct	  values	  
 
RPLP0 Ct 
0x 14.85 
13.59 
5x 16.01 
15.65 
25x 18.42 
18.17 
125x 20.62 
20.60 
625x 23.01 
23.03 
3125x 25.50 
25.49 
15,625x 28.41 
27.86 
     
9.2.1.2.2 Standard	  curves,	  extra	  figures	  	  
 
Figure 40: Dissociation curve for RPLP0 standard curve 
NDRG2 Ct 
0x 21.30 
21.23 
5x 23.35 
23.14 
25x 26.03 
25.92 
125x 28.12 
27.80 
625x 30.20 
30.60 
3125x 33.64 
34.80 
15,625x 34.45 
32.74 
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Figure 41: Amplification curve for NDRG2 standard curve 
 
9.2.1.2.3 Ct	  values	  for	  RPLP0	  and	  NDRG1-­‐4	  
The data (Ct values) was normalized by calculating ΔCt followed by ΔΔCt. The ΔΔCt values 
were normalized with the formula 2^ΔΔCt [Livak & Schmittgen, 2001]. 
 
Table 11: Ct values for RPLP0, NDRG1, NDRG2, NDRG3 and NDRG4 from colon tissue, HCT116, DLD-2, 
SW480 and LoVo – The values are obtained from qPCR for the cell lines, by using 25x cDNA. The number 0 was 
given when no Ct values were measured (NDRG1 in SW480 and NDRG4 for LoVo) and numbers in parentheses are 
values removed due to too much variation between the triplicates. 
Ct RPLP0 NDRG1 NDRG2 NDRG3 NDRG4 
Colon 24.99 
24.80 
24.56 
25.84 
26.21 
25.50 
28.23 
28.48 
28.32 
31.61 
31.63 
31.02 
33.08 
33.63 
32.98 
HCT116 20.81 
21.10 
20.99 
26.84 
26.82 
26.85 
28.38 
28.61 
28.13 
28.39 
28.56 
28.12 
33.49 
33.16 
32.26 
DLD-1 21.55 
21.96 
21.64 
32.95 
32.96 
(34.15) 
34.72 
33.33 
32.41 
28.05 
28.19 
28.13 
34.75 
33.56 
33.82 
SW480 23.34 
23.33 
23.88 
0 
0 
0 
33.85 
33.79 
32.49 
30.71 
30.32 
30.41 
34.27 
33.42 
34.46 
LoVo 27.54 
27.61 
27.75 
31.07 
30.88 
(34.13) 
33.58 
32.37 
33.02 
35.75 
35.72 
34.82 
0 
0 
0 
 
Table 12: ΔCt values for RPLP0, NDRG1, NDRG2, NDRG3 and NDRG4 from colon tissue, HCT116, DLD-2, 
SW480 and LoVo – The values are calculated from Ct values from table 8 by extracting NDRG1-4 Ct values from 
RPLP0 Ct values 
ΔCt ΔCt NDRG1 
(NDRG1-
ΔCt NDRG2 
(NDRG2-
ΔCt NDRG3 
(NDRG3-
ΔCt NDRG4 
(NDRG4-
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RPLP0) RPLP0) RPLP0) RPLP0) 
Colon 0.85 
1.41 
0.94 
3.24 
3.68 
3.76 
6.62 
6.83 
6.46 
8.09 
8.83 
8.42 
HCT116 6.03 
5.72 
5.86 
7.57 
7.51 
7.14 
7.58 
7.46 
7.13 
12.68 
12.06 
11.27 
DLD-1 11.4 
11 
(-21.64) 
13.17 
11.37 
10.77 
6.50 
6.23 
6.49 
13.2 
11.6 
12.18 
SW480 -23.34 
-23.33 
-23.88 
10.51 
10.46 
8.61 
7.37 
6.99 
6.53 
11.03 
10.09 
10.58 
LoVo 3.53 
3.27 
(-27.75) 
6.04 
4.76 
5.27 
8.21 
8.11 
7.07 
-27.54 
-27.61 
-27.75 
 
 
Table 13: ΔΔCt values for RPLP0, NDRG1, NDRG2, NDRG3 and NDRG4 from colon tissue, HCT116, DLD-2, 
SW480 and LoVo – The values are calculated from the table 9 by extracting ΔCt values from NDRG1-4 with ΔCt 
values of RPLP0 
ΔΔCt ΔΔCt NDRG1 
(ΔNDRG1-
ΔRPLP0) 
ΔΔCt NDRG2 
(ΔNDRG2-
ΔRPLP0) 
ΔΔCt NDRG3 
(ΔNDRG3-
ΔRPLP0) 
ΔΔCt NDRG4 
(ΔNDRG4-
ΔRPLP0) 
Colon 0.00 0.00 0.00 0.00 
HCT116 5.18 
4.31 
4.92 
4.33 
3.83 
3.83 
0.96 
0.63 
0.67 
4.59 
3.23 
2.85 
DLD-1 10.55 
9.59 
(-22.58) 
9.93 
7.69 
7.01 
-0.12 
-0.60 
0.03 
5.11 
2.77 
3.76 
SW480 (-24.19) 
(-24.74) 
(-24.82) 
7.27 
6.78 
4.85 
0.75 
0.16 
0.07 
2.94 
1.26 
2.16 
LoVo 2.68 
1.86 
(-28.69) 
2.80 
1.08 
1.51 
1.59 
1.28 
0.61 
(-36.63) 
(-36.44) 
(-36.17) 
 
Table 14: Normalization of RPLP0, NDRG1, NDRG2, NDRG3 and NDRG4 from colon tissue, HCT116, DLD-
2, SW480 and LoVo – The data from table 10 are normalized according to Livak & Schmittgen (2001). 
Normalization 
(2^- ΔΔCt) 
NDRG1 NDRG2 NDRG3 NDRG4 
Colon 1 1 1 1 
HCT116 0.03 
0.05 
0.03 
0.05 
0.07 
0.10 
0.51 
0.65 
0.63 
0.04 
0.11 
0.14 
DLD-1 0.00 
0.00 
(ND) 
0.00 
0.00 
0.01 
1.09 
1.52 
0.98 
0.03 
0.15 
0.07 
SW480 ND 0.01 0.59 0.13 
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ND 
ND 
0.01 
0.03 
0.90 
0.95 
0.42 
0.22 
LoVo 0.16 
0.18 
(ND) 
0.14 
0.47 
0.35 
0.33 
0.41 
0.66 
ND 
ND 
ND 
	  
Table 15: P-values for mRNA expression of the NDRG family measured in cancerous cell lines – The p-values 
are calculated by a students T-test in GraphPad Prism 6, and all the data set for NDRG1-4 was compared to healthy 
colon. 
p-values NDRG1 NDRG2 NDRG3 NDRG4 
HCT116 0.0001 0.0002 0.0104 0.0010 
DLD-1 0.0002 0.0000 0.3581 0.0014 
SW480 ND 0.0001 0.2359 0.0127 
LoVo 0.0484 0.0196 0.0316 ND 
 
	  
Figure 42: mRNA expression of the NDRG family – Ct values from table 11, which is normalized with healthy 
colon tissue. The normalized data can be found in table 14. * indicates p-values from table 15. 
 
9.2.2 Methylation	  status	  
The bisulfite products were obtained with bisulfite specific primers. The blue area indicates the 
primer binding sites and the green area is the CpG site. The numbers on the left are the 
nucleotide numbers, counted from the binding site, in such a way that the numbers matches the 
sequencing figure 43 and 44 below.  
 
HC
T1
16
DL
D-
1
SW
48
0
Lo
Vo
0.0
0.5
1.0
1.5
2.0
mRNA expression of the NDRG family
NDRG1
NDRG2
NDRG3
NDRG4
0.04
ND ND ND
0.59
0.07
1.20
0.003
0.08
0.22
0.32
0.46
0.02
0.1
0.81
0.26
*
* *
*
*
*
*
*
*
*
*
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9.2.2.1 NDRG1	  sequence	  and	  sequencing	  results	  
 
1 ACAAACCTCGCCTGGCTCCCAGCTGGTGCTGAAGCTCGTCAGTTCACCAT  
39 CCGCCCTCGGCTTCCGCGGGGCGCTGGGCCGCCAGCCTCGGCACCGTCCT  
89 TTCCTTTCTCCCTCGCGTTAGGTAAGCCCGCGCCCTCTTCTCCCAGGCGC  
139 GACGCGGAGCAGAAAGGGGCCGCCCGTGCGGTGCCGCTGGAGCGCCAGGA 
189 CCGCCCTTTGTAGCCCCGCGTACTCCAGGAGTAAGCGCCCCGGAGCTGCA 
239 AGTGCGCGGTCACCCCGGGGCGCGGGCGCGAGGGGGCTTTGGGTGCAGAC  
241 ACCGCTGAAGTGGGGGGTTCAATTACGGAAAGGGAGGAAAAAAAGACAGG 
 
 
Figure 43: Genomic sequencing for NDRG1 – The cell lines SW480, DLD-1 and HCT116 were bisulfite treated 
and sequenced with bisulfite-NDRG1 primer. SssS1 (positive) was sequenced to compare to the results. The 
sequences cover a ∼250 bp area, but due to primer binding, the results are only demonstrated from 40 bp to 160 bp. A) 
SW480 B) SssI C) HCT116 D) DLD-1 
 
9.2.2.2 NDRG4	  sequence	  and	  sequencing	  results	  
 
1 gggggagggggacgacgccccagaggcccctgagcccctggttcttcccg  
27 accctaagggcttttctccctcggttcccaggcggcgacggcgggtagcg  
77 cgaagcagcaggcgcaggggcgctgggatggggatgtctctgcaggtcta 
127 aggttccccttgggagtctaaacaaagactacggcagcgccgtcccctcc 
A 
B 
C 
D 
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177 cccgggaacccgacgccgcgcggccacagggggcctggaggggcgggcag  
 
 
Figure 44: Genomic sequencing for NDRG4 - The cell lines DLD-1 and HCT116 were bisulfite treated and 
sequenced with bisulfite-NDRG1 primer. Genomic DNA (negative) and SssS1 (positive) were also sequenced to 
compare to the results. The sequences are ∼200 bp, but due to primer binding, the results are demonstrated from 40 bp 
to 170 bp. A) Genomic DNA B) SssI C) HCT116 D) DLD-1 
 
 
A 
B 
C 
D 
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9.2.3 MBPs	  mRNA	  expression	  
 
Figure 45: MBPs mRNA expression – Replication of conventional PCR of MeCP2, Kaiso and MBD2a mRNA in 
CRC cell line HCT116, DLD-1, SW480 and LoVo. The four mRNAs were all detected in HCT116, DLD-1 and 
SW480 both times. The second time (right) had a lower expression of RPLP0, which explains the lower expressions 
of LoVo mRNA. Thus the two tests show similar results. The four mRNAs are generally less expressed in LoVo. A 1 
kb marker (#1333 from Thermo Scientific) was used. 
 
9.2.4 ChIP	  
Table 16: Ct values for ChIP-NDRG4 with qPCR  
Ct Anti-H3 Anti-IgG Anti-MeCP2 Anti-MBD2 Input 
HCT116 25.42 
25.81 
26.43 
27.46 
28.46 
28.30 
25.62 
28.00 
27.57 
29.20 
29.39 
(31.81) 
(44.65) 
0 
0 
SW480 28.36 
28.06 
27.30 
28.49 
(26.84) 
28.81 
26.14 
26.00 
25.75 
26.78 
26.53 
26.91 
0 
(44.34) 
0 
 
Table 17: Normalization for ChIP-NDRG4 - the data was normalized against non-immune-IgG 
Normalization non-immune-IgG Anti-MeCP2 Anti-MBD2 
HCT116 0.261 
0.177 
0.310 
0.889 
0.207 
0.529 
0.085 
0.088 
SW480 0.914 
0.595 
4.659 
4.170 
2.990 
2.888 
First try    Second try 
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Table 18: Student T-tests for ChIP-NDRG4 – the data was obtained by comparing anti-MeCP2 and anti-MBD2 
with anti-IgG in GraphPad Prism 6. 
P-values Anti-MeCP2 Anti-MBD2 
HCT116 0.274 0.052 
SW480 0.011 0.031 
 
9.2.5 ChIP	  dissociation	  curves	  
 
Figure 46: ChIP dissociation curves – The dissociation curves demonstrates that the water sample had another 
dissociation temperature. 
 
9.3 Primers 
Table 19: Primers used 
 Direction Sequence (5’à3’) Annealing 
temp. 
(°C) 
Fragment 
size (bp) 
Use 
CDK-4 Forward TTTAGGATGGTAATTGGTTTTGT 55 250 Bisulfite 
treatment 
control 
CDK-4 Reverse ATCTCCAATTACCAACAACAACTATA 55 250 Bisulfite 
treatment 
control 
Kaiso Forward AAGCTTTATCGTTTACATCCAT 52 120 mRNA/ChIP 
Kaiso Reverse ATACCCAATACCATCATCCTT 52 120 mRNA/ChIP 
MBD2a Forward AGAGCGGGAAGAGGATGGAT 60 386 mRNA 
MBD2a Reverse TCGTTGTGGGTCTGATTTCACT 60 386 mRNA 
MeCP2 Forward TCAGAGGGTGTGCAGGTGAA 58 270 WB/ChIP 
MeCP2 Reverse TGGAAAAGGCATCTTGACAAGGA 58 270 WB/ChIP 
NDRG1 Forward ACAACCCCCTCTTCAACTACG 52 - qPCR 
!
Dissociation Curve 
0515 chIP (SW480), Test med NDRG4-chIP primer (H3, IgG, MeCP2, INPUT(SW480), 
g.DNA og H2O).mxp 
Water 
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NDRG1 Reverse TGGACCACTTCCACGTTACTC 52 - qPCR 
NDRG2 Forward ACCTCGTTCCTCAAGATGGCT 52 - qPCR 
NDRG2 Reverse TGGGACAGGGTGCGAGAG 52 - qPCR 
NDRG3 Forward AATGCATATTGCCCAAGACA 52 - qPCR 
NDRG3 Reverse CTCTGCGTCCATTGTAGGAA 52 - qPCR 
NDRG4 Forward GGGCCTCAACCACAAACTCT 52 - qPCR 
NDRG4 Reverse CATCCACGTGACACACCAC 52 - qPCR 
RPLP0 Forward GCTTCCTGGAGGGTGTCC 52 120 qPCR/mRNA 
RPLP0 Reverse GGACTCGTTTGTACCCGTTG 52 120 qPCR/mRNA 
 
9.3.1 Design	  of	  primers	  
The primers used to determine the methylation status of NDRG1-4 were designed in the 
program MethPrimer [MethPrimer⎥Li Lab, UCSF, n.d]. The sequences of the humane NDRG1-4 
mRNA were found on UCSC Genome informatics webpage [UCSC Genome Bioinformatics, 
n.d.], by using the following search terms:   
• Group: Mammal 
• Genome: Human 
• Search term: NDRG1-4, Variant 1, mRNA 
o Promoter/Upstream by 5000 bp 
o 5´UTR exons 
o 3´UTR exons 
o Introns 
The genome sequence was copied into Microsoft Word to enable a search for regions with a 
high amount of CG. The region was copied into to the MethPrimer program where CpG island 
prediction was used for the selection of primers for bisulfite sequencing PCR [Li & Dahiya, 
2002]. 
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Figure 47: MethPrimer – To design primers, the program MethPrimer were used [MethPrimer⎥Li Lab, UCSF, n.d]. 
The program predicts CpG islands and places the primer in the promoter region or 5000 bp upstream of the promoter 
region, so that it is close to the transcription start site. 
 
9.4 Antibodies 
Primary 
Antibody 
Target Species Dilution Band size 
(kDa) 
Catalogue no. 
β-actin Western Blot Mouse 1 µL in 10 mL 43 A5441, Sigma 
GFP Western Blot/ 
esiRNA 
Mouse 2 µL in 10 mL 27 G1546, Sigma and 
SC-8334, Santa 
Cruz  
Histone 3 
(H3) 
ChIP Rabbit 1 µL in 10 mL 17 ab1791, Abcam 
Kaiso Western Blot Mouse 2 µL in 10 mL 80 ab12723, Abcam 
MBD2 Western Blot Rabbit 8 µL in 10 mL 43 ab38646, Abcam 
MBD2a Western Blot Rabbit 4 µL in 10 mL 43 ab3754, Abcam 
MeCP2 Western Blot Rabbit 4 µL in 10 mL 56 SAB4800012, 
sigma 
MeCP2 ChIP Rabbit 2 µL in 10 mL 56 ab2828, Abcam 
MYC Western Blot Mouse 4 µL in 10 mL 62 626801, 
BioLegend 
Non-immune-
IgG 
ChIP - - - P-2025-48 
Epigentek 
 
Secondary 
antibody 
Type Species Dilution Catalogue no. 
HRP-anti-mouse Western 
Blot/ChIP 
Goat 2 µL in 10 mL Pierce 
HRP-anti-rabbit Western 
Blot/ChIP 
Goat 2 µL in 10 mL Pierce 
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9.5 Failed methods and their results 
The elucidation of the methylation status of NDRG required four different approaches before it 
was successful.   
 
9.5.1 Methyl	  specific	  primer	  PCR	  
To elucidate methylation status a positive control (SAM and SssI methylase treated genomic 
DNA), a negative control (genomic DNA from Roche) and H2O were used to test the primer set 
as illustrated in figure 48. Each set consisted of a forward primer and a reverse primer. For each 
of the tested genes, a methylated and an unmethylated specific primer set were used. The 
primers were designed to have an annealing temperature of 60°C and were previously tested by 
Kirsten Olsen. Therefore the first temperatures used can be found in table 20. 
 
Table 20: MSP primers and the used annealing temperatures used 
MSP First try,  
Annealing 
temp. 
Second try,  
Annealing 
temp.  
Third try,  
Annealing 
temp. 
Fourth try,  
Annealing 
temp. 
Fifth try,  
Annealing 
temp. 
NDRG1 
Methylated, set 1 
60 - 60 60 60 
NDRG1 
Umethylated, set 
2 
60 - 55 50 52 
NDRG1 
Methylated, set 3 
60 60 - 55 65 
NDRG1 
Umethylated, set 
4 
55 50 - 65 52 
NDRG3 
Methylated, set 5 
60 55 55 60 52 
NDRG3 
Umethylated, set 
6 
55 50 55 65 52 
NDRG4 
Methylated, set 7 
65 - 60 55 55 
NDRG4 
Umethylated, set 
8 
60 60 60 65 62 
NDRG4 
Methylated, set 9 
65 60 55 65 62 
NDRG4 
Umethylated, set 
10 
60 - 55 50 65 
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Figure 48: Methyl specific primers (MSP) – To elucidate if a promoter region was methylated, a MSP set was used 
to detect methylated and unmethylated regions, thus one of the sets functioned as a controls. 
 
9.5.1.1 Touchdown	  PCR	  
Touchdown PCR is conventional PCR, but the annealing temperature differs in the cycles, as 
illustrated in figure 49. The black underlining in segment two and three illustrates ‘autoflex’, 
which means that for each cycle run, the annealing temperature dropped 0.5°C. The fourth and 
fifth segment was run as a normal PCR reaction. 
The temperatures were selected based on previously obtained PCR for bisulfite-specific NDRG3 
and NDRG4 primers, which was designed to work with an annealing temperature of 60°C. 
Primer	  set	  1 
Primer	  set	  2 
Primer	  set	  5 
Primer	  set	  6 
Primer	  set	  7 
Primer	  set	  8 
Primer	  set	  9 
Primer	  set	  10 
MPS	  third	  try 
Primer	  set	  1 
Primer	  set	  2 
Primer	  set	  3 
Primer	  set	  4 
Primer	  set	  5 
Primer	  set	  6 
Primer	  set	  7 
Primer	  set	  8 
Primer	  set	  9 
Primer	  set	  10 
MPS	  fifth	  try 
  Page 91 of 94 
NDRG3 did not give results when the annealing temperature was 60°C, but showed weak bands 
when decreased to 50°C. NDRG4 gave some bands at 60°C, but showed bands for all the 
samples, when it was decreased to 50°C. Therefore the touchdown PCR was performed to 
optimize the annealing temperature.  
 
Figure 49: Touchdown PCR – Touchdown PCR consists of 5 stages where the temperature simulates conventional 
PCR, but stage 2 and 3 have autoflex. Autoflex makes the annealing temperature go down between each cycle run. 
The temperature starts where results are obtained and decreases until an expected functional annealing temperature. 
The 4th and 5th segment is a normal PCR reaction. 
 
The touchdown program was performed with the same primers (bisulfite specific NDRG3 and 
NDRG4 primers), which were run on a 1% agarose gel. The results are shown in figure 48, 
which shows contamination in the water.  
 
Figure 50: Touchdown PCR – Touchdown PCR was performed with bisulfite specific primers for NDRG3 and 
NDRG4 on genomic DNA, SssI and H2O. The results show bands in the positive control (SssI), NC (genomic DNA) 
and for H2O.  
 
9.5.2 Dissociation	  curve	  
Methylated samples contain a higher level of cytosine than unmethylated samples. Therefore, 
the dissociation temperature of the samples dissociation must differ, since the CpG had more 
hydrogen bound than AgT. Therefore qPCR was performed as previously described (see page 
31) with bisulfite specific primers. The experiment was performed twice as seen in figure 49 and 
50. 
NC PC H2 O NC PC H2 O 
NDRG3 NDRG4 
∼ 	  150	  kDa 
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The first time only genomic DNA (NC) showed an “alternative peak” for NDRG1, however the 
NC is not methylated. Since the NC’s lower dissociation temperature is likely due to 
primerdimer. No results were obtained for NDRG3. NDRG4 demonstrated only one peak 
indicating that all of the products were the same, as seen in figure 49. 
 
 
 
Figure 51: Dissociation curves with MSPs first time – The dissociation was done for genomic DNA (NC), SssI 
(PC) and H2O with bisulfite specific primers for NDRG1, NDRG3 and NDRG4. For the NDRG1 primer set, NC had 
two peaks: a low dissociation peak at 70°C for one of the triplicates, and a high peak for all triplicates at 78°C. PC 
also peaked at the high temperature. However, no dissociation temperature was detected when the NDRG3 primers 
were used. The bisulfite specific primers for NDRG4 gave high peak for genomic DNA (yellow) and a smaller peak 
for genomic DNA. 
To verify the results, the method was replicated. The second result shown in figure 50 illustrates 
the same tendency as the first attempt. However, NDRG1 had an alternative dissociation 
temperature, but the second time it was for NTC (water). Again, NDRG3 showed no dissociation 
curve, indicating that no product was present. NDRG4 NC had two dissociation peaks, but this 
was probably due to primerdimer.  
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Figure 52: Dissociation curves with MSPs second time – The dissociation was done for genomic DNA, SssI and 
H2O with bisulfite specific primers for NDRG1, NDRG3 and NDRG4. For the NDRG1 primer set, all the samples had 
a dissociation peak at 78°C, except for one of the water samples (green), which had a dissociation temperature at 
72°C. No dissociation temperature was detected, when the NDRG3 primers were used. The bisulfite specific primers 
for NDRG4 showed a high peak at 78°C for genomic DNA (yellow), while genomic DNA (purple) had two peaks at 
71°C and 78°C. 
These results did not show the expected different peaks. A higher dissociation temperature was 
expected for the positive control, while a lower dissociation temperature was expected for the 
NC, which is unmethylated. Therefore the method was dismissed. 
 
9.5.3 Methylated	  DNA	  Immunoprecipitation	  
The EpiQuik™ MeDIP kit detects methylated DNA by using antibodies that bind to methylated 
cytosine. The assay was performed according to the manufacture’s protocol. 
The wells were treated with either anti-5-methylcytosine or anti-IgG (control) and sonicated 
DNA was added. Next, the DNA was washed and incubated with a DNA release buffer with 
proteinaseK. Finally the samples were washed and treated with DNA release buffer, followed by 
a wash. The samples were tested by conventional PCR and run on a 1% agarose gel with a 1 kb 
marker (#1333 from Thermo Scientific) as seen in figure 51. 
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Figure 53: MeDIP – The results were run on a 1% agarose gel. 1st time: ∼100 kDa unclear bands for the tested 
samples. HCT116 cell extracted DNA was used with MBD2a primers, which gave the expected 386 kDa band. 2nd 
time: The tested samples did not show any bands. Here the positive control was DNA from SW480 tested with 
RPLP0, which showed the expected size at 120 kDa.  
MeDIP	  
SW480	  input 
SW480	  (IgG) 
SW480	  (5-­‐MC) 
LoVo	  input 
LoVo	  (5-­‐MC) 
Control 
386	  kDa 
∼ 	  100	  kDa 
2.	  time 
H2 O SW480	  (IgG) 
SW480	  input 
LoVo	  (IgG) 
LoVo	  input 
Control 
386	  kDa 
∼ 	  100	  kDa 
1.	  time 
